University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2016

Monocyte and Macrophage Apoptosis and Activation During
HIV-1 Infection and Antiretroviral Therapy
Sean Christopher Patro
University of Pennsylvania, patro@mail.med.upenn.edu

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
Medical Immunology Commons, and the Virology Commons

Recommended Citation
Patro, Sean Christopher, "Monocyte and Macrophage Apoptosis and Activation During HIV-1 Infection and
Antiretroviral Therapy" (2016). Publicly Accessible Penn Dissertations. 1936.
https://repository.upenn.edu/edissertations/1936

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1936
For more information, please contact repository@pobox.upenn.edu.

Monocyte and Macrophage Apoptosis and Activation During HIV-1 Infection and
Antiretroviral Therapy
Abstract
Monocytes and macrophages represent a cell lineage integral to multiple aspects of HIV-1 infection,
dissemination, and pathogenesis. They also play a fundamental role in innate host defense and may act
as a tissue-privileged viral reservoir during all stages of infection. In the current ART-era of the HIV
pandemic, HIV-seropositive patients can maintain undetectable viral loads for years. Nevertheless, this
population faces central nervous system, cardiovascular, and other HIV-related co-morbidities, many of
which are characterized by underlying monocyte/macrophage contributions. To investigate the regulation
of the survival and activation profiles of monocytes/macrophages during HIV-1 infection in vivo, we
performed the following sets of experiments: (1) we determined monocyte apoptosis profiles in
previously uncharacterized highly viremic HIV (+) donors and assessed monocyte gene expression
associated with monocyte apoptosis outcome; (2) we tested the impact of ART and CCR5 antagonism
during advanced HIV-1 infection on the reversal of monocyte/macrophage activation; (3) we tested the
impact of the interferon stimulated genes (ISGs) IFI6 and IFI27 as an underlying mechanism regulating
monocyte apoptosis in the context of HIV-1 infection. Our results indicate both constitutive and oxidative
stress-induced monocyte apoptosis are elevated in HIV (+) individuals with viral loads above 40,000 HIV-1
copies/mL and are associated with decreasing CD4 count. Furthermore, elevated apoptosis is associated
with a shift in interferon stimulated gene and Bcl-2 family gene expression. Longitudinal analysis of ART
treatment during advanced HIV-1 infection (nadir CD4 count < 100 cells/mm3) demonstrated differential
reversal of cell-associated and soluble biomarkers of monocyte/macrophage activation. We show the
addition of CCR5 antagonism (Maraviroc) does not impact the reversal of monocyte/macrophage
activation beyond the impact of standard ART alone. Finally, we investigate the roles of the ISGs IFI6 and
IFI27 in the regulation of monocyte apoptosis in vitro. Our work demonstrates the impact of viral and host
pressures on monocyte survival/apoptosis and activation state during distinct stages of HIV-1 infection.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Luis J. Montaner

Keywords
Activation, Apoptosis, HIV, Macrophage, Monocyte, Therapy

Subject Categories
Allergy and Immunology | Immunology and Infectious Disease | Medical Immunology | Microbiology |
Virology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1936

MONOCYTE AND MACROPHAGE APOPTOSIS AND ACTIVATION DURING
HIV-1 INFECTION AND ANTIRETROVIRAL THERAPY
Sean C. Patro
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2016

Supervisor of Dissertation

____________________________
Luis J. Montaner, D.V.M., D.Phil.
Professor of Medicine

Graduate Group Chairperson

____________________________
Daniel S. Kessler, Ph.D
Associate Professor of Cell and Developmental Biology

Dissertation Committee
Michael R. Betts, Ph.D., Associate Professor of Microbiology
Ronald G. Collman, M.D., Professor of Medicine
Dennis L. Kolson, M.D., Ph.D., Professor of Neurology
Louise C. Showe, Ph.D., Professor of Molecular and Cellular Oncogenesis

MONOCYTE AND MACROPHAGE APOPTOSIS AND ACTIVATION
DURING HIV-1 INFECTION AND ANTIRETROVIRAL THERAPY
COPYRIGHT
2016
Sean Christopher Patro

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 3.0
License
To view a copy of this license, visit
http://creativecommons.org/licenses/by-ny-sa/2.0/

This thesis is dedicated to my family.
Thank you for your unwavering support and love.

iii

ACKNOWLEDGEMENTS
I want to thank my partner Brittany Good for walking with me on this journey
towards a PhD.
I want to thank my mentor, Luis. J. Montaner, for the opportunity to be a part of
this team. His commitment, guidance, and enthusiasm have been critical in my
maturation as a scientist. I thank all the members of the Montaner lab for
providing a stimulating environment for the growth of the scientific mind.

Beth Peterson
Jennifer Dubin
Costin Tomescu
Emmanouil (Manolis) Papasavvas
Matthew Fair
Shaheed Abdulhaqq

Brian Ross
Jocelin Joseph
Charity Calloway
Farzaneh Sabahi
Livio Azzoni
Agnieszka (Agnes) Mackiewicz

I would like to thank and acknowledge the contributors to the work performed in
this dissertation: researchers at Wistar, clinical coordinators and physicians,
rotation students, and the HIV-patients who volunteered to participate in these
studies.
I would also like to thank my thesis committee, Michael R. Betts, Ronald G.
Collman, Dennis L. Kolson, and Louise C. Showe for their guidance along the
way.

Wistar Institute:
Deborah D. Davis
Ramana V. Davuluri
Sharmistha Pal
Yingtao Bi
David Schultz
Henry Hoff
Andrew V. Kossenkov
Celia Chang
Jeffrey Faust

Coordinators/
Physicians:
Kenneth Lynn
Karam C. Mounzer
Jay R. Kostman

The CADIRIS Study:
Juan G. Sierra-Madero
Mohammed S. Rassool
Ian Sanne

UPENN/Wistar Rotation
Students:
Megan Wise
Amanda Versace
Alana Sharp

UPENN CFAR:
Ronald G. Collman
James A. Hoxie
Farida Shaheen
Steven Bryan

iv

I. ABSTRACT

MONOCYTE AND MACROPHAGE APOPTOSIS AND ACTIVATION
DURING HIV-1 INFECTION AND ANTIRETROVIRAL THERAPY
Sean C. Patro
Dr. Luis J. Montaner

Monocytes and macrophages represent a cell lineage integral to multiple aspects
of HIV-1 infection, dissemination, and pathogenesis. They also play a
fundamental role in innate host defense and may act as a tissue-privileged viral
reservoir during all stages of infection. In the current ART-era of the HIV
pandemic, HIV-seropositive patients can maintain undetectable viral loads for
years. Nevertheless, this population faces central nervous system,
cardiovascular, and other HIV-related co-morbidities, many of which are
characterized by underlying monocyte/macrophage contributions. To investigate
the regulation of the survival and activation profiles of monocytes/macrophages
during HIV-1 infection in vivo, we performed the following sets of experiments: (1)
we determined monocyte apoptosis profiles in previously uncharacterized highly
viremic HIV (+) donors and assessed monocyte gene expression associated with
monocyte apoptosis outcome; (2) we tested the impact of ART and CCR5
antagonism during advanced HIV-1 infection on the reversal of
monocyte/macrophage activation; (3) we tested the impact of the interferon
stimulated genes (ISGs) IFI6 and IFI27 as an underlying mechanism regulating
V

monocyte apoptosis in the context of HIV-1 infection. Our results indicate both
constitutive and oxidative stress-induced monocyte apoptosis are elevated in HIV
(+) individuals with viral loads above 40,000 HIV-1 copies/mL and are associated
with decreasing CD4 count. Furthermore, elevated apoptosis is associated with a
shift in interferon stimulated gene and Bcl-2 family gene expression. Longitudinal
analysis of ART treatment during advanced HIV-1 infection (nadir CD4 count <
100 cells/mm3) demonstrated differential reversal of cell-associated and soluble
biomarkers of monocyte/macrophage activation. We show the addition of CCR5
antagonism (Maraviroc) does not impact the reversal of monocyte/macrophage
activation beyond the impact of standard ART alone. Finally, we investigate the
roles of the ISGs IFI6 and IFI27 in the regulation of monocyte apoptosis in vitro.
Our work demonstrates the impact of viral and host pressures on monocyte
survival/apoptosis and activation state during distinct stages of HIV-1 infection.
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1.1 The HIV-1 pandemic: The early years, infection, and treatment
The earliest clinical reports of HIV in the United States occurred in the
summer of 1981 (1, 2). Unusual presentations of Pneumocystis carinii
pneumonia, Kaposi’s sarcoma, and other infections typically associated with
immunosuppression were documented in previously healthy homosexual men in
California and New York City (3-6). In September 1982, the CDC coined the term
AIDS (acquired immune deficiency syndrome) to describe the growing epidemic
(7). In 1983, two research groups isolated a retrovirus from AIDS patients, Robert
Gallo and colleagues in the United States (termed HTLV-III, human Tlymphotropic virus type III) and Françoise Barré-Sinoussi, Luc Montagnier, and
colleagues in France (termed LAV, lymphadenopathy-associated virus) (8, 9).
This retrovirus would become known as HIV and the etiological agents of AIDS.

The natural disease course of HIV-1 infection can be divided into three
stages: acute, chronic, and advanced infection/AIDS (Figure 1.1 (10), Reviewed
in (11)). Acute infection typically lasts 9 to 12 weeks and can present clinically as
a flu-like acute retroviral syndrome. This period is characterized by peak viral
replication, viral seeding of host lymphoid tissue, and severe CD4 depletion of
gut-associated lymphoid tissue (12). During chronic infection, viremia is partially
controlled by host immune responses, reaching a relatively stable viral load setpoint (13, 14). The length of chronic infection is highly variable, and viral set point
is predictive of time to progression to AIDS (15, 16). Progression to AIDS
(advanced infection) occurs when CD4 count decreases below 200 cells/mm3 or
2

with the onset of AIDS-associated opportunistic infections, as defined per CDC
guidelines.

Figure 1.1: HIV-1 natural disease course.
HIV-1 viral load (red, HIV-1 copies/mL) and CD4 count (blue, CD4 T-cells/mm3)
during untreated HIV-1 infection. The infection stages are acute, chronic, and
advanced infection/AIDS. [10]

The first drug to treat HIV infection, azidothymidine (AZT/ZDV), was
approved by the FDA on March 19, 1987 and belongs to the reverse
transcriptase inhibitor class of anti-retroviral drugs, specifically a nucleoside
reverse transcriptase inhibitor (NRTI). The current arsenal of anti-retroviral drugs
targets multiple stages of the viral life cycle and includes reverse transcriptase
inhibitors (nucleoside (NRTI), non-nucleoside (NNRTI), and nucleotide (NtRTI)),
protease inhibitors, integrase inhibitors, and entry inhibitors (Table 1.1). By the
3

mid 1990s, combination therapy (multiple anti-retroviral drugs, with at least two
from different classes) began the era of cART/HAART (combined/highly active
anti-retroviral therapy), drastically extending the lifespan and improving prognosis
of HIV-infected individuals.

Table 1.1: HIV antiretroviral therapy (ART).
ART drugs, abbreviations, year approved, and company sorted by class.
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1.2 HIV target cells: CD4 T-cells and monocytes/macrophages

1.2.1 HIV CD4 T-cell infection and activation
HIV viral particles target host immune cells expressing the receptor CD4
and one of two co-receptors, CCR5 and CXCR4 (17). As it follows, the primary
targets of HIV-1 infection are CD4 T-cells (CCR5/CXCR4) of the adaptive
immune system and monocytes and macrophages (CCR5) of the innate immune
system.
Depletion, activation, and dysfunction of CD4 T-cells have come to be the
signature of HIV-1 infection (12, 18, 19). CD4 T-cell loss during HIV-1 infection is
mediated by multiple mechanisms including cytopathic effects by viral replication,
immune clearance of infected cells by CD8 T-cells and natural killer cells (13, 14,
20, 21), and bystander killing of uninfected CD4 T-cells by interactions with viral
proteins and apoptotic ligands on antigen presenting cells (Figure 1.2, Reviewed
in (18, 22)). In addition, the activation state of CD4 and/or CD8 T-cells (defined
by the expression of CD38 and/or HLA-DR) is associated with both disease
progression and poor immunological response to therapy (16, 23-25). It is also
appreciated that sustained viremia, immune activation, and exposure to microbial
products during HIV infection leads to a state of T-cell exhaustion in both CD4
and CD8 compartments mediated by chronic stimulation and induction of
inhibitory ligands and receptors such as PDL-1/PDL-2-PD-1, among others (2628).
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Figure 1.2: Mechanisms of CD4 T-cell death during HIV-1 infection.
During untreated infection, CD4 T-cell death results from apoptotic pressure of
HIV-1 proteins, activation-induced death, and extrinsic apoptosis mediated by
death ligands, often presented by on antigen presenting cells (APC). (Adapted
from [22].)

1.2.2 Monocyte heterogeneity and infection by HIV/SIV
Monocytes are phagocytic cells that are generated from myeloid
progenitors in bone marrow, circulate in blood, and migrate into tissue, maturing
into macrophages in response to chemotactic and inflammatory signals (29).
Blood monocytes exist in heterogeneous populations, similar in both humans and
rhesus macaques, and much of our understanding of monocyte heterogeneity
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and phenotypes in both healthy and HIV/SIV-infected conditions has been
obtained from non-human primate (NHP) models (29-31). Classical monocytes
(CD14++CD16-) represent the largest subset under normal conditions while the
intermediate (CD14++CD16+) and non-classical (CD14+CD16++) subsets are
expanded during HIV/SIV-infection and other inflammatory conditions (30, 32-36)
(Figure 1.3). Separate transcriptional profiles have been described for CD16- and
CD16+ subsets (37), and BrdU pulse-chase has demonstrated that maturation of
monocytes in blood progresses from classical to intermediate to non-classical
monocytes upon differentiation (29). Furthermore, the CD16+ subsets bear
significance based on permissiveness to infection (30, 38-40) and
immunophenotypic similarity to infected macrophages in tissue (41, 42). In light
of such heterogeneity, subset composition and phenotype are an important
consideration of monocyte studies regarding all stages of HIV-infection.

Figure 1.3: Human monocyte subsets.
Human blood monocytes are divided into classical (CD14++CD16-), intermediate
(CD14++CD16+), and non-classical (CD14+CD16++) subsets by expression of
CD14 and CD16 (left). Shown are representative HIV (-) (middle) and HIV (+)
(right) donors.
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Among HIV-infected individuals (both viremic and ART-suppressed), it is
estimated that less than 0.1% of circulating monocytes harbor HIV-1 DNA (38,
43, 44). The degree of ongoing replication in monocytes in vivo is a source of
debate as early studies found monocytes from HIV (+) patients could seed
infection of PHA-stimulated PBMC co-culture in vitro (45) while more recent
studies have proposed the hypothesis that tissue macrophages may reflect
phagocytosed infected T-cells rather than macrophage infection (46).Additionally,
viral sequence analysis has suggested low levels of monocyte virus production
(38). The CD16+ subsets of blood monocytes has been proposed to be
permissive to infection as they harbor higher levels of HIV DNA when compared
to the CD16- fraction, explained by higher expression of CCR5 and expression of
high molecular weight APOBEC3G (compared to restrictive, low molecular
weight APOBEC3G in CD14+CD16- monocytes) (40). Similarly, intermediate
monocytes are reported to have the highest levels of SIV DNA in acutely infected
rhesus macaques (30). The most direct evidence for the importance of infection
of CD16+ monocytes is supported by the detection of p28/p24-positive, CD16+
macrophages in brain of SIVE macaques and autopsy of HIVE patients (41, 47).

The resistance of monocytes to infection compared to tissue macrophages
has been assigned to the activity of a number of host intrinsic factors and other
mechanisms that limit infection and replication in monocytes (Figure 1.4,
Reviewed in (48, 49)). Restriction of monocyte infection is considered to occur
post-entry and pre-integration (50). Transcriptional profiling of monocytes
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suggests expression of the cytidine deaminases APOBEC3G and APOBEC3A,
which are downregulated with macrophage differentiation, may contribute to
restriction of replication in monocytes (51). A low level of nucleotide precursors,
limiting reverse transcription, may contribute to low infection in monocytes,
macrophages, and dendritic cells; however, this block is removed by the
SIV/HIV-2 accessory protein Vpx (52, 53). The restriction factor responsible for
this activity was discovered to be the deoxynucleoside triphosphate
phosphohydrolase SAMHD1 (54, 55). In addition to host restriction factors,
microRNA activity may also limit HIV-1 transcription in monocytes, either directly
targeting viral mRNA or indirectly by the repression of CycT1 (56, 57). Together,
factors above and the recently described interferon stimulated gene (ISG)
viperin/RSAD2 (58) limit HIV-1 infection in monocytes.
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Figure 1.4: Barriers to HIV-1 replication in monocytes.
Shown are intrinsic host restriction factors that contribute to restriction of HIV-1
replication in monocytes (top left) and differences in susceptibility of select
monocyte subsets (bottom left) and tissue macrophages (right). [49]

1.2.3 Role of macrophages as viral reservoirs
Although macrophages are typically ascribed a secondary role compared
to resting memory CD4 T-cells in discussions of HIV/SIV persistence and viral
reservoirs, multiple observations over the past 20 years makes a strong
argument for their involvement. This argument is based on evidence of
productively infected macrophages in lymphoid tissue (59) and macrophage
sequence evolution in AIDS patients (60). In non-human primates models,
rhesus macaques that are severely CD4-depleted, by either natural progression
or severely pathogenic SHIV infection, maintain high levels of viral replication
through macrophage sources of virus (61-63). This evidence is supported by
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studies of SIV infection with antibody-mediated CD4 T-cell-depletion, in which
high levels of CD68+ macrophage infection are observed in rectal biopsies (64)
and high proportions of viral RNA-positive macrophages are observed in
lymphoid tissue and brain (65). This concept of macrophages as an immuneprivileged reservoir in various tissue sites is reviewed in (49). As noted above,
these observations stand in contrast to recent data that suggests macrophages
acquire viral DNA by phagocytosis of infected CD4 T-cells and therefore do not
reflect productive infection (46).

1.2.4 Role of monocytes and macrophages in HIV CNS and gut
pathogenesis
CNS Pathogenesis
Macrophage infection within the CNS has been appreciated since the
early years of the HIV-1 epidemic, described in post-mortem HIV patients with
CNS pathology (66, 67). SIV models have demonstrated that the virus enters the
brain early during acute infection (41, 68) and the primary target of HIV/SIV
infection within the brain is the perivascular macrophage (CD68+CD163+), which
are immunophenotypically similar to expanded CD14+/-CD16+ monocytes
observed during infection, suggesting a mechanism of CNS entry (41, 47, 69).
This population is distinct from resident microglia and “recently infiltrated”
macrophages (MAC387+) recruited from peripheral blood during inflammatory
conditions (70-73). The association of monocyte activation and CNS recruitment
with direct measurements of neuronal injury and neurocognitive dysfunction in
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both HIV-infection and SIV-models supports a vital role of the
monocyte/macrophage in CNS pathogenesis (Figure 1.5, Reviewed in (49, 73,
74)). These include an expansion of activated subsets in blood and brain (32, 47,
69, 75, 76), increased monocyte turnover in blood (71), monocyte ISG
expression (Discussed in Section 1.4), and soluble markers of
monocyte/macrophage activation, including sCD14 in blood (77, 78) and
cerebrospinal fluid (CSF) (47, 79) and sCD163 in blood (80). Once virus and
inflammatory/activated macrophages reach the brain, the cellular mechanisms of
neuronal injury include the activity of viral proteins, activating chemokines and
cytokines, and neurotransmitters (Reviewed in (49, 81, 82)).

Figure 1.5: Monocytes and macrophages in HIV-1 pathogenesis.
Shown is an overview of the contribution of monocytes/macrophages to HIV-1
pathogenesis, including CNS, during acute, chronic, and advanced infection
(AIDS) and ART treatment. [74]
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Gut Pathogenesis
Under normal conditions, macrophages within the gastrointestinal mucosa
are maintained in an anti-inflammatory, functionally inert state (though still
functionally competent) despite the presence of GI bacteria through TGF-β
production by resident stromal cells (83). This mechanism also downregulates
CD4 and CCR5 expression conferring a resistance to HIV-1 infection in gut
macrophages not observed in other tissue macrophages, such as vaginal
macrophages (84, 85). However, during chronic, untreated SIV/HIV infection, gut
epithelial barrier dysfunction results in leakage of microbial products that drive
TLR-mediated activation and overall increases in immune activation (86-90).
Tissue macrophage activation is proposed to be an important determinant of
outcome as markers of plasma LPS (sCD14) predict mortality in HIV-1 infected
individuals (91). Plasma sCD14 and markers of gut epithelial dysfunction also
predict mortality among ART-suppressed individuals (92, 93). During chronic
HIV-1 infection, high levels of CD68+CD163+ macrophages are recruited to gut
mucosa by CCL2/CCR2 and integrin-β7-mediated mechanisms (94). Within gut
mucosa, these macrophages may contribute to epithelial barrier dysfunction and
microbial translocation by increased production of pro-inflammatory cytokines
and chemokines (TNF-α, IL-1β, CCL5, CXCL9, CXCL10) and impaired
phagocytic activity (88, 94).
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1.3: Modulation of monocyte and macrophage apoptosis during HIV-1/SIV
infection
Unlike CD4 T-cells, the apoptotic fate of monocytes during chronic
infection and elevated HIV/SIV viremia is less clear, as different ex vivo and in
vitro studies have reported both anti-apoptotic and pro-apoptotic mechanisms
and outcomes. HIV-1/SIV can directly impact apoptosis in monocyte and
macrophages (Figure 1.6) and monocyte/macrophage-mediated apoptosis of
non-myeloid bystander cells, particularly CD4 T-cells (Reviewed in (18, 22)).

Figure 1.6: Pro- and anti-apoptotic pressures on monocytes/macrophages
during HIV-1 infection/exposure.
Summary of apoptotic impacts of HIV-1 infection/exposure observed ex vivo and
with infection/exposure of monocytes/MDM in vitro.
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1.3.1: SIV infection of NHP models in vivo
The NHP model of SIV-infected rhesus macaques has generated
significant insight regarding HIV-1 pressure on monocyte and macrophage
apoptosis. Early descriptions of macrophage apoptosis (macrophages and
microglia) within the brain were observed with CNS pathology of rhesus
macaques infected with neurovirulent SIV (95). The ability of in vivo SIV infection
to sensitize monocytes and dendritic cells (DC) to constitutive and receptormediated apoptosis has been well-characterized (96). Interestingly, elevated
plasma FasL (Fas ligand) observed in rhesus macaque infection was not
observed in the non-pathogenic model of SIV infection in African green monkeys
(AGM). Furthermore, in vivo BrdU labeling of monocytes in SIV-infection showed
that elevated monocyte turnover is associated with macrophage apoptosis in
lymph nodes (CD163+TUNEL+) and faster progression to AIDS (70). Elevated
monocyte turnover has also been associated with the severity of SIV CNS
pathology and the monocyte/macrophage activation marker, sCD163 (71). The
association of sCD163 with monocyte turnover offers additional insight when
interpreting monocyte/macrophage activation reflected by elevated sCD163
during HIV-1 infection (Discussed in Section 1.4). Indeed, turnover of monocytes
in NHP models (70, 71) may suggest a contribution of cell death and
monocyte/macrophage dysfunction in compromised host defense during
advanced SIV/HIV infection (97). The relationship between monocyte activation
and soluble markers of activation during viremia and ART-mediated viral
suppression will be addressed in this thesis.
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1.3.2: Monocyte regulation in HIV infection: Pro-apoptotic
While findings in NHP models have demonstrated pro-apoptotic impacts of
SIV-infection, in vitro studies of HIV-1 exposure/infection of monocytes and
macrophages and ex vivo studies on monocytes from HIV-infected patients have
yielded both pro- and anti-apoptotic findings. It is of paramount importance to
interpret ex vivo HIV-1 monocyte apoptosis data in the context of clinical status
(HIV-1 viral load and CD4 count). In a study of HIV-exposed seronegative (ESN),
HIV (+), and HIV (-) individuals, Velilla et al described increased constitutive and
in vitro HIV-1 induced monocyte apoptosis in the ESN and HIV (+) group relative
to the HIV (-) group (98). However, viral load, CD4 count, and ART-status were
not reported in the HIV (+) group. A study of STAT1 expression demonstrated
elevated constitutive monocyte apoptosis and plasma TRAIL in the HIV (+)
viremic group (off-ART, median viral load = 94,000 copies/mL) relative to the HIV
(-) group and an association of STAT1 protein expression and monocyte
apoptosis in the HIV (+) viremic group (99). Regarding myeloid dendritic cells
(mDC), decreased Bcl-2 expression and increased apoptosis (Caspase-3+) was
observed in HIV (+) (mean viral load=89,700 copies/mL) relative to HIV (-)
donors, and apoptosis was associated with viral load CD8 T-cell activation
(CD38+) and decreased with ART (100). Taken together, pro-apoptotic outcomes
in monocyte studies in HIV infection have pointed to a relationship between high
viral load and cell death.
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1.3.3: Monocyte regulation in HIV infection: Anti-apoptotic
However, ex vivo HIV-1 studies have also demonstrated mechanisms of
HIV-1 induced monocyte apoptosis resistance. Cosenza et al observed evidence
of apoptosis resistance in HIVE-CNS, as p24+ cells had lower percentages of
TUNEL+ cells than the overall CNS macrophage/microglia population (101).
Furthermore, ex vivo analysis of gene expression from circulating monocytes and
in vitro HIV-1 exposure/infection of whole PBMC supported gene modulation
consistent with anti-apoptotic regulation (Reviewed in (102)). Specifically, a
stable 38-gene anti-apoptosis gene signature was noted in monocytes from
viremic HIV (+) donors (mean VL=32,000 copies/mL) compared to HIV (-) donors
and was associated with resistance to induced apoptosis (103). Gene and
protein expression data evidence engagement of CCR5 contributing to prosurvival signaling (p38/ERK/MAPK) by viral envelope interactions and/or natural
CCR5 ligands (i.e., β-chemokines). Additional investigation of target apoptosis
gene families from the parent array confirmed the apoptosis resistance
phenotype in monocytes of additional HIV (+) patients and demonstrated the
contribution of elevated intracellular zinc content, zinc importer expression,
metallothionein expression (mean VL=39,294 copies/mL) (104) and Rb1 protein
activity (mean VL=59,269 copies/mL) (105) to HIV-1 mediated monocyte
apoptosis resistance. These data suggest viral replication and CCR5 ligands may
promote monocyte survival, which stands in contrast to pro-apoptotic findings
reviewed above. The relationship between pro- and anti-apoptotic regulation of
monocytes in HIV infection will be addressed in this thesis.
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1.3.4: MDM HIV infection in vitro: Pro-apoptotic
HIV-1 infection of MDM in vitro increases sensitivity to TRAIL-mediated
apoptosis. Recombinant TRAIL and TRAIL-receptor agonists were initially
explored in vitro as a means of purging HIV-1 infected CD4 T-cells and
macrophages (106). In vitro HIV-1 infection of MDM and comparison of primary
peripheral blood lymphocytes in HIV (-) and HIV (+) donors demonstrated higher
TRAIL-receptor expression in HIV (+) conditions, and MDM from HIV (+) donors
(relative to HIV (-) donors) were more sensitive to recombinant TRAIL-mediated
apoptosis. Downstream of receptor expression, HIV infection/exposure was
shown to sensitize macrophages to apoptosis by inhibiting Akt-1 activity in the
Akt-1-FOXO3a pathway (107, 108). Furthermore, Laforge et al provided an
extensive in vitro characterization of HIV-1 induced monocyte and dendritic cell
apoptosis sensitization (96). Infection of MDM increased both activation induced
(LPS+IFN-γ) and ligand mediated apoptosis (TRAIL) by the down-regulation of
the anti-apoptotic molecules FLIP and Mcl-1 and up-regulation of the proapoptotic Bax and Bak. Similarly, Zhu et al demonstrated infection with a HIVpseudotype sensitized MDM to TRAIL-mediated apoptosis by down-regulation of
the TRAIL decoy receptors DcR1 and DcR2 (TNFRSF10C and TNFRSF10D)
and the anti-apoptotic protein FLIP (109). Additionally, the accessory protein Vpr
has been shown to induce apoptosis in monocytes in vitro (110, 111).

In vivo and in vitro evidence has accumulated of HIV-induced TRAIL (both
membrane and soluble) production by monocytes and macrophages as a
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mechanism of bystander apoptosis induction. In a study of 107 HIV (+)
individuals, sTRAIL was elevated in viremic and suppressed patients relative to
HIV (-) donors, and sTRAIL and mTRAIL was highly inducible in monocytes in
vitro in a CD4-dependent mechanism by a type-I interferon/STAT pathway (112).
The ability of HIV-infection and type-I interferons to induce MDM sTRAIL/mTRAIL
has been further characterized to be IRF-1/IRF-7-dependent (113). Finally, Kim
et al demonstrated robust TRAIL induction in MDM in pathogenic infection
settings (SIV-RM in vivo, HIV in vitro) but not in non-pathogenic systems (SIVchimpanzee, SM, AGM), suggesting a TRAIL-mediated role of monocytes and
macrophages in CD4 T-cell depletion (114). Overall, induction of apoptosis after
MDM infection is primarily associated with external regulation of activation
(TRAIL, LPS, IFN-γ).

1.3.5: MDM HIV infection in vitro: Anti-apoptotic
One the other hand, anti-apoptotic impact has been demonstrated by
infection and HIV-1 proteins in vitro, including Tat, Nef, and Env (115-117)
(Reviewed in (118, 119)). This impact is complimented by the notion that viral or
disease pressures that drive monocyte activation and/or differentiation mediate
an increasingly pro-survival phenotype (110, 120-125). Specifically, Zhang et al
demonstrated HIV-1 infection of MDM resulted in increased Bcl-2 expression,
and treatment with exogenous HIV-Tat (126) was able to recapitulate apoptosis
resistance to TRAIL-mediated apoptosis (127). Furthermore, it was demonstrated
that HIV-Nef could mediate apoptosis resistance in MDM, mediated by Bad
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inactivation by hyper-phosphorylation (128). HIV-1 infection of MDM was also
described to upregulate anti-apoptotic Bcl2 and Bcl2L1 and downregulate Bad
and Bax, the former through a TNF-α-dependent mechanism (129). HIV-induced
M-CSF production has been implicated in monocyte/macrophage-associated
pathogenesis (Reviewed in (130)). Specifically, Env expression induced an antiapoptotic macrophage state, characterized by increased Mcl-1 and Bcl2-A1
expression and decreased TRAIL-R1 expression by a M-CSF dependent
mechanism (131). Additionally, as noted above, in vitro engagement of CCR5 by
virus can mediate Rb1 protein activity resulting in apoptosis resistance (103,
105). Interestingly, osteopontin, elevated during SIVE, also protects human
monocytes from induced apoptosis in vitro (132). Overall, apoptosis resistance is
primarily associated with virus/receptor interactions, intrinsic, and/or paracrine
regulation.

1.4: Modulation of monocyte interferon gene expression during HIV-1
infection
The predominance of ISG expression in monocytes and macrophages is a
hallmark of HIV-1 infection and has been well described in both in vitro studies
and patient populations spanning all stages of infection.

Early studies demonstrated elevated plasma interferons in HIV-1 infected
patients during both acute (133) and advanced (134) infection as well as the
impact of ART on plasma IFN-α (135). Additionally, plasma IFN-α has been
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associated with plasma LPS (but not viral load), suggesting that microbial
translocation may serve as a source of sustained type-I interferon-driven
activation (86). Monocyte ISG expression in the context of HIV-1 exposure or
infection has been demonstrated both ex vivo and in vitro. Early studies
established HIV-1 treatment of monocytes could induce IFN-α production
independent of productive infection (136). Microarray studies have extensively
characterized ISG induction from HIV-1 infection/exposure of MDM in vitro, (113,
137-140), temporal phases of ISG induction (138, 139), and an overlap of type-I
ISG expression profiles between patient derived monocytes and in vitro
stimulated monocytes (140). Additionally, the HIV-1 accessory proteins Tat and
Vpr are independently sufficient to induce ISG expression in MDM in vitro (141,
142). Microarray and gene expression studies of primary patient monocytes have
also demonstrated robust ISG expression during chronic infection associated
with viremia (140, 143-146) that is decreased with viral suppression (147). ISG
expression has also been characterized relative to infection stage in human
lymphoid tissue in a cross-sectional study (148) and longitudinally in PBMC in the
SIV NHP model (149).

This ISG profile is further supported by the detection of ISGs at the protein
level, including both monocyte/macrophage cell-associated and plasma soluble
proteins. Plasma CXCL10 is a well-characterized marker of ISG expression
during HIV-1 infection, as it is elevated in viremic patients (144, 146, 150-152)
and associated with HIV-1-associated neuronal injury (144, 146) in a manner
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similar to monocyte ISG expression (145). Additionally, ex vivo culture of
duodenal tissue, enriched for macrophage infiltrate in viremic HIV (+) donors, has
demonstrated elevated CXCL10 production relative to tissue from HIV (-) donors
(94). Longitudinal studies have described increased plasma CXCL10 during STI
(scheduled treatment interruption) (153) and decreased CXCL10 during ART
(135); however, cross-sectional studies suggest viremic suppression is not
accompanied by complete reversal, as plasma CXCL10 is elevated in ARTtreated patients (150, 152) and elite controllers (152) relative to HIV (-) donors.
CD169 (Sialoadhesin, SN, SIGLEC1) is a surface-expressed ISG (IFN-α, IFN-γ
inducible) on monocytes, macrophages, and dendritic cells and is highly
expressed during HIV-1 infection (143, 146, 154-156) and other inflammatory
diseases (155, 157). CD169 can facilitate trans-infection of target cells by both
monocytes and dendritic cells (156, 158, 159). CD169 expression was elevated
in progressive stages of infection a HIV-1 cross-sectional study (154) and
reversed with ART in a SIV longitudinal study (160).

Monocyte/macrophage ISG expression also has a significant bystander
effect on T-cells and other immune cells. As noted above, ex vivo and in vitro
studies suggests HIV-1 can induce monocyte/macrophage TRAIL expression
(membrane and soluble) by an IFN-dependent mechanism that may contribute to
bystander CD4 T-cell apoptosis (22, 112, 113). Monocyte/macrophage ISG
expression may also play a role in T-cell exhaustion during HIV-1 infection.
Specifically, the ligands, PD-L1 and PD-L2 are expressed on monocytes and
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macrophages during HIV-1 infection and can be up-regulated by factors present
during infection including virus particles, TLR-agonists, and type-I interferons (27,
28, 161) (Reviewed in (162)). PD-L1/L2 ligand interactions with PD-1 on
activated T-cells can mediate CD4 and CD8 T-cell exhaustion during HIV-1
infection (26, 27, 163). Finally, type-I interferon driven BAFF (B cell-activating
factor) expression and secretion by monocytes may also drive B-cell dysfunction
observed during HIV-1 infection (164).

While ISG expression is associated with disease progression in HIV/SIV
infection (165, 166), ISGs also include HIV restriction factors that inhibit/limit
replication in monocytes (48, 49, 167, 168). While comprehensive study is not a
focus of this thesis, we will briefly highlight major HIV-1 restriction factors
described to date. The APOBEC3 family of cytidine deaminase hypermutates
incoming HIV proviral DNA (169), and SAMHD1 limits the pools of dNTPs
available for reverse transcription (54, 55). IFITM proteins (IFITM1-3), members
of the ISG12 family, have also been shown to inhibit HIV replication (170).
Tetherin (BST2, CD317) restricts budding of virus particles (171). Finally, Mx2
has recently been ascribed post-entry/pre-integration restriction activity (172).
The overall benefit (HIV restriction) or burden (association with disease
progression and persistence by PD-L1/IL-10 (27, 161, 173)) of ISG expression
remains in debate. This thesis will address whether ISG induction in monocytes
relative to viral load is related to changes in monocyte apoptosis.
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1.5: Cell-associated and soluble biomarkers of monocyte and macrophage
activation during HIV-1 infection and ART
It is established that sustained T-cell activation during HIV-1 infection is
associated with disease progression and sub-optimal CD4 T-cell recovery after
ART (16, 23-25). Nonetheless, the significance of monocyte and macrophage
activation, independent of infection, has returned to prominence due to the
association with gut epithelial barrier dysfunction and microbial translocation (77,
86-89, 91-93, 174, 175). The phases of this activation sequela, gut barrier
dysfunction (apoptosis, I-FABP, zonulin) (91-93), microbial translocation (plasma
LPS, plasma 16S rDNA) (77, 86, 87, 91, 174, 175), and biomarkers of innate
activation (sCD14) (77, 78, 86, 91, 174, 175), have been investigated for their
association with one another and predictive value of clinical and therapeutic
outcome. Furthermore, activation of monocytes and macrophages (by virus,
microbial translocation, immune cross-talk, and other sources) remains a
potential source of inflammation that may not be fully reversed during ART
(Figure 1.7) (80, 86, 91, 150, 174, 176-179). We will address the relationship
between markers of innate monocyte/macrophage activation and ART-mediated
viral suppression in advanced infection.
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Figure 1.7: Biomarkers of monocyte and macrophage activation during HIV1 infection.
Shown are major cell-associated biomarkers of monocyte/macrophage activation
during SIV/HIV-1 infection.

1.5.1: Cell Associated Biomarkers
The expansion of CD16+ monocyte subsets, including CD14++CD16+
intermediate monocyte subset, has been described during HIV-1 (32-36) and SIV
viremia (30) and are associated with HIV pathogenesis (32, 47, 150). Elevated
CD16+ monocyte subsets may indicate long-term inflammation as similar
elevations have been described in patients with cardiovascular disease in HIV (-)
(35) and ART-suppressed cohorts (180). CD14++CD16+ monocytes are also
elevated in elite controllers compared to HIV (-) controls, supporting evidence of
ongoing innate activation despite viral control (181). Regarding ART, the
intermediate monocyte subset was decreased in patients treated during early
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infection, but not chronic infection (177), and cross-sectional comparisons have
demonstrated suppressed patients reach comparable levels to HIV (-) donors
(35).

CD163, the hemoglobin/haptoglobin receptor, is expressed on blood
monocytes tissue macrophages (182) and can be shed, as sCD163, by
ADAM17/TACE-cleavage during activated/TLR-stimulated conditions (177, 183).
CD163 expression is increased on intermediate monocytes of HIV (+) individuals
(31) and is highly expressed on macrophage infiltrates of CNS, cardiac, and gut
tissue during HIV/SIV infection (69, 72, 94, 184).

1.5.2: Soluble Biomarkers
Soluble biomarkers of monocyte/macrophage activation are also wellcharacterized during HIV infection, including sCD14 and sCD163. Elevated
sCD14 has been described as a marker of HIV-associated microbial
translocation and increased plasma LPS (86, 152, 185). Longitudinal ART
studies have found elevated sCD14 levels persist despite viral suppression (86,
174, 177) and are only partially resolved after extended ART (174, 175). In
addition, cross-sectional comparisons have demonstrated ART patients do not
resolve sCD14 to the level of HIV (-) donors (91, 152, 174, 178, 179).

Soluble CD163, shed from activated monocytes and macrophages, is
elevated during SIV/HIV infection and associated with both cardiac and CNS
26

pathogenesis (36, 71, 80, 150, 152, 176, 177, 179). Soluble CD163 was reduced
to HIV (-) levels in patients treated during early infection but not in those treated
during chronic infection (177); however, unlike the intermediate monocyte subset,
cross-sectional studies suggest sCD163 does not reach levels of HIV (-) donors
upon viral suppression (80, 150, 176, 179).

The relationship between monocyte subsets, viral load, monocyte
apoptosis, soluble markers of activation, and ART-mediated viral suppression will
be addressed in this thesis.

1.6 Scope of Thesis
This thesis provides new data on monocyte biology during HIV-1 infection
addressing regulation of monocyte apoptosis, innate immune activation, viral
load, and ART-mediated viral suppression. We investigate the presence of
activated monocyte subsets in patients with high viral load/low CD4 count and
examine modulation of monocyte apoptosis sensitivity and transcription profiles
(ISG expression) relative to viral load/CD4 count. We characterize the induction
of genes associated with apoptosis regulation as well as the impact of overexpression of target genes on apoptotic outcome in vitro. Additionally, we
investigate the impact of ART-mediated viral suppression on
monocyte/macrophage activation profiles in HIV-1 patients initiating therapy
during advanced HIV-1 infection (CD4 count less than 100 cells/mm3). We also
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investigate the impact of CCR5 antagonism during ART on the reversal of
monocyte/macrophage activation profiles.
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CHAPTER 2: Shift in monocyte apoptosis with
increasing viral load and change in apoptosis-related
ISG/Bcl2 family gene expression in HIV-1 infected
patients during chronic infection

2.1 Introduction
2.2 Ex vivo HIV (+) monocyte apoptosis characterization and RNA sequencing
2.2.1 Pilot RNA sequencing
2.2.2 Ex vivo expression of the ISG12 family highlights candidate
ISG/apoptosis-regulatory genes
2.2.3 In vitro regulation of IFI6 and IFI27 expression in primary human
monocytes
2.3 Shift in monocyte apoptosis with increasing viral load and change in
apoptosis-related ISG/Bcl2 family gene expression in HIV-1 infected patients
during chronic infection
2.3.1 Monocyte apoptosis is elevated in HIV-1 patients with high viremia
2.3.2 Markers of innate immune activation are increased with HIV infection
but do not associate with change in monocyte apoptosis
2.3.3 Apoptosis-related ISG family gene expression is altered in
association with viral load
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2.3.4 Multivariate analysis identifies genes associated with changes in
constitutive and induced apoptosis in HIV infection
2.4 Discussion, limitations, and future directions
2.5 Materials
2.5.1 Pilot RNA sequencing and analysis
2.5.2 Donor population
2.5.3 Monocyte and CD4 T-cell isolation and characterization
2.5.4 Plasma monocyte/macrophage activation markers
2.5.5 Quantitative real-time PCR
2.5.6 Apoptosis induction assay
2.5.7 Flow cytometry gating and analysis
2.5.8 Statistical analysis
2.5.9 Multivariate linear regression modeling
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2.1 Introduction
While HIV-1 infection is characterized by compromised adaptive immunity
with CD4 T-cell loss in tissue (12) and peripheral blood (18, 19), the loss of
monocytes and macrophages is less evident. The impact of HIV-1 viremia on
monocyte gene expression (103, 140, 147, 161, 186) and function (32, 33, 40,
143, 153) is largely independent of productive infection, as less than 0.1% of
circulating monocytes are estimated to harbor integrated HIV-1 DNA (38, 43, 44).
However, exposure to viral particles and proteins, microbial products, and host
products (inflammatory cytokines) can modulate monocyte function (27, 102,
140, 147, 158, 161, 187) and apoptosis (96, 99, 103, 109, 127, 131) during HIV-1
infection.

Unlike CD4 T-cells, the apoptotic fate of monocytes during elevated
HIV/SIV viremia is less clear, as ex vivo and in vitro studies have reported both
anti-apoptotic (103-105, 127, 131) and pro-apoptotic (96, 99, 109) mechanisms
and outcomes (Figure 1.6, Section 1.3). Gene expression studies have identified
a predominant anti-apoptosis gene signature in monocytes during chronic HIV-1
infection (103), and multiple studies have described anti-apoptosis mechanisms
ex vivo and in vitro including: engagement of CCR5 and pro-survival signaling
(p38/ERK/MAPK) (103), elevated intracellular zinc content, metallothionein
expression (104), elevated Rb1 protein activity (105), and M-CSF mediated
protection from TRAIL-induced apoptosis (131). Based on oxidative stress (188)
and increased expression of apoptotic ligands (22, 112, 113) observed during
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HIV infection, resistance to apoptosis has been tested by multiple induction
mechanisms (CdCl2, sFasL) in cross-sectional studies (103-105, 131). By
contrast, NHP SIV studies have characterized longitudinal changes under high
viremic settings and have shown higher monocyte turnover and elevated
activation markers in animals with rapid disease progression and
neuropathogenesis (69-71, 73, 75), suggesting a shift in monocyte viability upon
the onset of advanced infection. Other SIV and in vitro HIV-1 studies have
demonstrated pro-apoptotic outcomes of viral exposure based on modulation of
Bcl2 family genes (Bax, Bak, Mcl-1), downregulation of anti-apoptotic c-FLIP
proteins, and downregulation of TRAIL decoy receptors (96, 109). While the
impact of elevated viremia on monocyte activation has been characterized, no
HIV-1 study, to date, has measured monocyte apoptosis concurrently with
monocyte/macrophage activation to identify functional changes relative to one
another and elevated viral load. In addition, reports on anti-apoptotic outcomes in
monocytes from HIV-1 patients ex vivo have examined a limited range of viral
load (mean viral load, 32,000, 39,294, and 59,269 HIV-1 copies/mL for (103105)), requiring a more extensive analysis across a wider viral load distribution.

Herein, we reconcile data between independent reports of pro- and antiapoptotic gene expression and apoptosis outcomes by the ex vivo
characterization of circulating monocytes from a broad clinical spectrum of HIV-1
viremia in the absence of anti-retroviral therapy.
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2.2 Ex vivo HIV (+) monocyte apoptosis characterization and RNA
sequencing

2.2.1 Pilot RNA sequencing
A pilot experiment was designed to utilize RNA sequencing in isolated
CD4 T-cells and monocytes from viremic HIV-1 patients to investigate gene
expression in order to confirm and expand upon previous microarray findings
(Reviewed in (102)). Apoptosis characterization and RNA-sequencing was
performed on two samples of each HIV (-), HIV (+) LVL (low viral load), and HIV
(+) HVL (high viral load) group (Table 2.1). (LVL and HVL defined below/above
100,000 HIV-1 copies/mL in pilot.) Patients with low viral load were selected to
match previously reported profiles of monocyte apoptosis resistance in chronic
HIV (+) individuals (103-105). Patients with high viral load were chosen to the
investigate the unstudied monocyte apoptosis and gene expression profiles in
patients with viral load > 100,000 HIV-1 copies/mL.
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Table 2.1: Pilot donor characteristics.
Study group, viral load (and log viral load), and CD4 T-cell count of pilot study
cohort.

Gene expression was examined in pooled samples of two donors from
each group. The CD4 T-cell expression profile was not available in the HVL
group due to low CD4 T-cell recovery. The sequencing analysis pipeline and
read-purity is shown for each group, and mRNA reads represented 79-83% of
the sequences (Figure 2.1). Sequencing analysis was used to highlight candidate
genes regulating monocyte apoptosis (ISG/Bcl2 family) at different levels of HIV1 viremia (Pursued in Sections 2.2.2, 2.2.3, and 2.3).
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Figure 2.1: RNA sequencing analysis.
Shown is RNA sequencing analysis (A) and quality control/read purity (B) of the
two CD4 T-cell and three monocyte sequencing groups.

We targeted ISG expression as a set of genes expected to be induced in
monocytes from high viral load patients. Indeed, the HVL (+) monocytes
demonstrated the expected ISG induction, including Mx1, IFITs, OAS1, etc
(Figure 2.2, green box). Additionally, we observed differences in monocyte
p53/Bcl2 family gene expression, with a predominance for pro-apoptotic gene
expression at high viral load, and selected candidate genes for follow-up in an
expanded cohort (Figure 2.3; Follow-up Section 2.3).

35

Figure 2.2: Interferon stimulated gene expression during HIV-1 infection.
ISG expression profile of monocytes (left three columns) and CD4 T-cells (right
two columns) from HIV (-) and HIV (+) (low and high viremia) individuals.
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Figure 2.3: Monocyte apoptosis-related gene expression during HIV-1
viremia.
Apoptosis-regulatory gene expression profiles in monocytes of HIV (-) and HIV
(+) (low and high viremia) individuals. Pro-apoptotic genes designated with red
arrow, anti-apoptotic genes designated with green arrow.
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2.2.2 Ex vivo expression of the ISG12 family highlights candidate
ISG/apoptosis-regulatory genes
A primary goal of the RNA sequencing pilot was to highlight gene targets
that may regulate apoptosis in monocytes during HIV-1 infection. The
ISG12/FAM14 family was a lead of particular interest. This family is a group of
small, hydrophobic, interferon-inducible proteins, upregulated during viral
infection, with roles in both apoptosis regulation and virus-host interactions
(Reviewed in (189, 190)). IFI6 (G1P3, ISG6-16) has demonstrated inhibition of
mitochondrial-associated apoptosis in cancer cell lines (191, 192). Two other
members of the ISG12 family, IFI27 (ISG12) and IFITM2 (I-8D), have
demonstrated pro -apoptotic properties, mitochondrial localization, and induction
during viral infection (193-195). Interestingly, IFITM2 (along with IFITM1, IFITM3)
has been described to inhibit HIV-1 infection (170) and other viral infections
(196). The RNA sequencing expression illustrates that the ISG12 family is highly
expressed in the HIV (+) patient groups relative to the HIV (-) group like the
prototypic ISG, Mx1 (Figure 2.4). Of note, expression of the pro-apoptotic IFI27
expression was elevated in the HVL (+) group (relative to HIV (-)) by over 1000fold. Based on elevated expression in the pilot dataset and reported apoptosisregulatory function, we selected candidate ISG12 genes to characterize gene
regulation in vitro and gene expression in an expanded HIV (+) patient cohort.
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Figure 2.4: Monocyte ISG12 gene family expression during HIV-1 viremia.
Expression values of the prototypic ISG, Mx1, and the ISG12 gene are shown for
HIV (-) (blue), HIV (+) LVL (green), and HIV (+) HVL (red). (n=2 patient per
group) (RPKM=Reads Per Kilobase of transcript per Million mapped reads)

2.2.3 In vitro regulation of IFI6 and IFI27 expression in primary human
monocytes
Based on the ISG expression in HVL (+) monocytes, we first investigated
the regulation of the apoptosis-regulatory ISG12 genes, IFI6 and IFI27, in
primary human monocytes by IFN-α and HIV-1 treatment in vitro. IFI6 and IFI27
were robustly induced after 48 hours incubation with high-dose exogenous IFN-α
(0 to 5000 units/mL) (Figure 2.5, left column). IFN-α treatment induced a 2-log
fold induction for IFI6 (similar to Mx1) and a 4-log fold induction for IFI27 over
unstimulated conditions (Figure 2.5E). We also investigated induction at lower
levels of stimulation (0 to 50 U/mL) (Figure 2.6, right column) and observed IFI6
expression at very low doses (1-10 U/mL) (Figure 2.5B) and comparable IFI6 and
IFI27 raw expression at 25 to 50 U/mL (Figure 2.5B, D, representative of n = 2).
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Figure 2.5: Dose response of IFI6 and IFI27 expression in primary
monocytes.
Primary monocytes were treated with high-dose (0-5000 U/mL) (left) or low-dose
(0-50 U/mL) (right) IFN-α for 48 hours and gene expression was measured by
RT-PCR. Expression of IFI6 (A, B) and IFI27 (C, D) are shown. Fold-induction
over unstimulated (E, F) is shown for Mx1 (blue), IFI6 (red), and IFI27 (green).
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Figure 2.6: Kinetics of IFI6 and IFI27 expression in primary monocytes.
Primary monocytes were treated with high-dose (500 U/mL) (left) or low-dose (10
U/mL) (right) IFN-α for 72 hours and gene expression was measured by RTPCR. Expression of IFI6 (A, B) and IFI27 (C, D) are shown. Fold-induction over
baseline (E, F) is shown for Mx1 (blue), IFI6 (red), and IFI27 (green).
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Appropriate temporal regulation of IFI6 and IFI27 expression may be
essential for a concerted antiviral response. We conducted a 72 hour time course
of gene expression at two IFN-α doses (10 and 500 U/mL) (Figure 2.6). IFI6
expression peaked early, at 4 hours in the low-dose titration (Figure 2.6A) and
14-26 hours in the high-dose titration (Figure 2.6B), while IFI27 expression
persisted for 48 hours or longer post-stimulation (Figure 2.6C, D). Our findings
suggest IFI6 may be upregulated with lower stimulation (Figure 2.5B) and at
early time points (Figure 2.6A, B) compared to IFI27, which is highly expressed
with strong IFN-α stimulation and persistent at later time points in vitro (Figure
2.5C, Figure 2.6C, D), supporting a sequential regulation of ISG12 family
expression (190).

We then tested whether or not HIV-1 exposure would induce IFI6 and
IFI27 expression in monocytes similar to that of exogenous IFN-α treatment
(Figure 2.7). The experiment was designed to test the impact of exposure (and
limit productive infection) with monocytes cultured in the absence of
differentiating cytokines and in Teflon pots to prevent adherence-induced
differentiation. Monocytes were cultured for 48 hours and treated with IFN-α (500
U/mL), HIV-1 Bal, a lab-adapted CCR5-tropic lung isolate (50 ng p24/mL), HIV-1
Jago, a primary CCR5-tropic CSF isolate (50 ng p24/mL), and IFN-α plus HIV-1
combinations. HIV-1 Bal induced IFI6 and IFI27 to levels slightly lower than IFN-α
alone (Figure 2.7A, B) while HIV-1 Jago did not induce comparable ISG
induction. Interestingly, the combination of HIV-1 Bal and IFN-α induced IFI27
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expression one log higher than IFN-α alone, suggesting a potential additive or
synergistic induction. Such conclusions are limited due to the lack of replicates
and detailed follow-up; however, these data and pilot experiment data (Section
2.2.2) suggest HIV-1 can upregulate monocyte ISG12 family gene expression
and support follow-up in a comprehensive HIV (+) viremic cohort.

Figure 2.7: Monocyte IFI6 and IFI27 expression is induced by HIV-1 Bal, but
not Jago in vitro.
Primary monocytes were treated with IFN-α (500 U/mL), HIV-1 Bal or Jago (50
ng p24/mL), or a combination of IFN-α and HIV-1 for 48 hours gene expression
was measured by RT-PCR. Expression of IFI6 (A) and IFI27 (B) are shown. Foldinduction over baseline (C) is shown for Mx1 (blue), IFI6 (red), and IFI27 (green).
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2.3 Shift in monocyte apoptosis with increasing viral load and change in
apoptosis-related ISG/Bcl2 family gene expression in HIV-1 infected
patients during chronic infection

2.3.1 Monocyte apoptosis is elevated in HIV-1 patients with high viremia
Constitutive and induced monocyte apoptosis were examined in a cohort
of viremic patients (Table 2.2, 2.3) that included a wide range of viral load (2,2431,355,998 copies/mL) and CD4 count (26-801 cells/mm3). As expected, CD4
count was negatively associated with viral load (P = 0.0012, R = –0.5255). Flow
cytometry gating is shown in Figure 2.8.
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ID#

Gender

Age

Log Viral Load
(copies/mL)

CD4 Count
3
(Cells/mm )

1
3
4
5
7
8
9
10
11
12
13
14
15
16
17
18
19
20
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
40
Median
IQR

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F
M
M
F
M
F
M
M
M
M
F
M

46
23
44
33
48
33
52
37
40
41
54
56
40
27
49
24
27
43
56
24
22
60
30
52
47
52
49
45
47
36
28
27
24
84
44
43
30-49

5.44
4.97
3.35
5.67
3.72
4.38
4.93
3.97
6.13
4.56
3.96
5.64
5.49
5.18
4.31
4.18
5.54
4.61
4.59
4.85
4.15
5.45
4.64
4.41
5.00
5.07
4.58
4.61
5.29
4.64
4.62
4.10
5.04
4.29
5.76
4.64
4.31-5.29

26
773
801
380
209
428
497
620
61
425
483
27
264
202
289
653
99
329
293
464
370
107
605
142
333
133
309
163
101
617
515
325
225
190
186
309
163-464

1

Table 2.2: HIV (+) patient population.
Gender, age, log viral load, and CD4 T-cell count are shown (n=35).

Category

n

Female/Total

% Female

Age (Med, IQR)

HIV(-)

33

8/33

0.242

43.5 (28.5-54)*

HIV(+) Lo (<Log4.6)

14

3/14

0.214

46 (30-53)

HIV(+) Hi (>Log4.6)

21

1/21

0.048

40 (27.5-47)

Table 2.3: Gender and age of study groups.
Gender and age distribution of HIV (-) and HIV (+) sub-groups. *Age information
in the HIV (-) group available for 22/23 donors.
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Figure 2.8: Monocyte subsets and apoptosis gating.
(A) PBMC gated on singlets, intact cells, monocyte scatter profile, and
CD14/CD16 into non-classical (CD14+/CD16++), intermediate (CD14++/CD16+),
and classical (CD14++/CD16-) monocyte subsets. (B) Negatively purified
monocytes gated on singlets and intact cells and quantified for apoptosis by 7AAD and active caspase-3 staining. Percent apoptotic cells counted as total
caspase-3 positive cells (top right and bottom right quadrants).
Both constitutive and oxidative stress-induced apoptosis (20 μM CdCl2)
(197-200) (measured by active caspase-3) were elevated in monocytes from
patients above 40,000 (Log104.60) copies/mL (constitutive P = 0.0034, induced P
= 0.0002) when compared to lower viremic patients (Figure 2.9, 2.10A). Based
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Figure 2.9: Monocyte apoptosis characterization.
Representative 7-AAD/caspase-3 dot plots of monocytes from uninfected and
HIV(+) (14,000 and 439,508 copies/mL) individuals. Plots represent overnight
constitutive apoptosis (first row) and oxidative stress induced apoptosis (20 μM
CdCl2) (second row).
on the analysis of the primary variable, monocyte apoptosis, HIV (+) patient
variables are presented below and above a viral load cutoff of 40,000 HIV-1
copies/mL (Log104.60). Irrespective of viral load, increased T-cell apoptosis was
observed in all HIV (+) patients as compared to uninfected donors (data not
shown). Across all HIV (+) patients, constitutive and induced apoptosis were
positively associated with viral load (P = 0.0256, R = 0.3883 and P = 0.0002, R =
0.5974, respectively) and inversely associated with CD4 count (P = 0.0128, R = –
0.4288 and P = 0.0464, R = –0.3491, respectively) (Figure 2.10B, 2C).
Supporting a threshold effect of viral load, the correlation of viral load with
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apoptosis was not present if restricting to only patients above or below 40,000
copies/mL (all P values > 0.05, data not shown). Our data show higher HIV-1
viral load is associated with increased constitutive and induced apoptosis in
circulating monocytes.

Figure 2.10: Monocyte apoptosis is elevated in patients above 40,000
copies/mL and associated with viral load and CD4 T-cell count.
(A) Group-wise comparison of constitutive (left) and induced (right) apoptosis in
HIV(-) versus HIV(+) individuals and HIV(+) patients below versus above 40,000
(Log104.6) copies/mL. (B-C) Spearman ranked correlation of viral load (B) and
CD4 count (C) versus monocyte apoptosis levels in HIV(+) patients. The line on
the y-axis represents the median constitutive (8.48%) and induced (14.82%)
apoptosis levels of the HIV(-) group. Group-wise comparison displays median
and interquartile range using Mann-Whitney test (two-tailed) with P < 0.05
considered significant. Spearman (two-tailed) Rho and P values displayed with P
< 0.05 considered significant.
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2.3.2 Markers of innate immune activation are increased with HIV infection
but do not associate with change in monocyte apoptosis
We wanted to test if observed differences in apoptosis were associated
with monocyte/macrophage markers of activation in our cohort. Studies have
described CD14++CD16+ intermediate monocytes (30, 32, 34, 35, 73), plasma
sCD14 (86, 91, 151, 185), and plasma sCD163 (71, 176, 177, 201) as
biomarkers of monocyte/macrophage activation and pathogenesis during
SIV/HIV-1 infection. We found the CD14++/CD16+ intermediate subset and
plasma sCD163 were elevated in the HIV (+) group compared to controls (Figure
2.11A, columns 1, 3), but did not detect differences within the HIV (+) groups
(Figure 2.11B) or an association between these variables with viral load (Figure
2.11C), monocyte apoptosis (Figure 2.11D), or CD4 count (Figure 2.12A).
Conversely, plasma sCD14 concentration was associated with viral load (Figure
2.11C) and CD4 count (Figure 2.12A), but not monocyte apoptosis (Figure
2.11D, P = 0.1070). Below a CD4 count of 500 cells/mm3 (Figure 2.12B), CD4
count demonstrated a strong negative correlation with sCD14 (P < 0.0001) and
negatively trended with sCD163 (P = 0.0657). Taken together, these data
support the presence of monocyte/macrophage activation demonstrated by
elevated sCD163 and CD14++CD16+ monocytes and an association of sCD14
with viremia and CD4 count that is independent of changes in monocyte
apoptosis with viral load.
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Figure 2.11: Monocyte/macrophage activation in HIV (+) patient cohort.
(A-B) Group-wise comparison of percentage of intermediate CD14++/CD16+
monocytes (left), plasma sCD14 (middle), and plasma sCD163 (right) in HIV(-)
versus HIV(+) individuals (A) and HIV(+) patients below versus above 40,000
(Log104.6) copies/mL (B). (C-D) Spearman ranked correlation of viral load (C)
and induced apoptosis (D) versus monocyte/macrophage activation metrics.
Group-wise comparison displays median, interquartile range (box), and range
(whiskers) using Mann-Whitney test (two-tailed) with P < 0.05 considered
significant. Spearman (two-tailed) Rho and P values displayed with P < 0.05
considered significant.
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Figure 2.12: Monocyte/macrophage activation and CD4 count in HIV (+)
patient cohort.
(A-B) Spearman ranked correlation of CD4 count with percentage of intermediate
CD14++CD16+ monocytes (left), plasma sCD14 (middle), and plasma sCD163
(right) in total HIV(+) cohort (A) and HIV(+) patients below CD4 count of 500
cells/mm3 (B). Spearman (two-tailed) Rho and P values displayed with P < 0.05
considered significant.

2.3.3 Apoptosis-related ISG family gene expression is altered in association
with viral load
Pilot and in vitro experiments (Section 2.2) highlighted candidate
apoptosis-regulatory gene families for follow-up in an expanded HIV (+) patient
study. We chose to investigate monocyte expression of candidate p53 (105, 202,
203), Bcl2/cytochrome C (204-208), and ISG (170, 189-194, 196) family genes in
viremic HIV (+) individuals (Table 2.4). RT-PCR analysis at time of isolation
showed significantly higher Rb1 expression in the total HIV (+) group versus the
HIV (-) group (P = 0.0100) but no association with viral load, consistent with
reports of Rb1 contributions to apoptosis resistance (105) in circulating
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Table 2.4: Apoptosis related p53, Bcl2/cytochrome C, and ISG family genes
measured by absolute quantification RT-PCR.
Gene symbol, apoptotic impact, primers, expression in HIV (-) and HIV (+)
groups, and P for HIV (-) versus total HIV (+) group comparison.

monocytes during chronic HIV-1 infection. Within the Bcl2/cytochrome C genes
analyzed, the HIV (+) group was characterized by lower Bcl-w (P = 0.0169) and
higher cytochrome C gene expression (P = 0.0392); however, neither gene was
associated with viral load. In contrast, Mx1 and the apoptosis-regulatory ISG12
members (IFI6, IFI27, IFITM2) showed higher expression in the HIV (+) group,
and IFI27 and IFITM2 expression was elevated in the HIV (+) group above
40,000 copies/mL relative to the HIV (+) group below 40,000 copies/mL (Figure
2.13A). The apoptosis-related ISGs (IFI6, IFI27, IFITM2) were also positively
associated with viral load (Figure 2.13B). Taken together, our data demonstrate a
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shift in monocyte gene expression with HIV-1 infection and increasing viral load
that may support modulation of apoptosis outcome.

Figure 2.13: Monocyte ISG12 family expression is elevated in patients
above 40,000 copies/mL and associated with viral load.
(A) Group-wise comparison IFI6, IFI27, and IFITM2 gene expression in HIV(+)
patients below versus above 40,000 (Log104.6) copies/mL. (B) Spearman ranked
correlation of viral load versus monocyte gene expression. Group-wise
comparison displays median, interquartile range (box), and range (whiskers)
using Mann-Whitney test (two-tailed) with P < 0.05 considered significant.
Spearman (two-tailed) Rho and P values displayed with P < 0.05 considered
significant.

2.3.4 Multivariate analysis identifies genes associated with changes in
constitutive and induced apoptosis in HIV infection
Although gene expression within target gene families was correlated (p53,
pro-apoptotic Bcl2-genes, and ISGs) (Figure 2.14), only IFITM2 was associated
with constitutive apoptosis, indicating that single gene analysis could not a reflect
change in both constitutive and induced apoptosis outcome. Multivariable
stepwise regression modeling was applied to evaluate if the combination of viral
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Figure 2.14: Gene expression correlation of p53, Bcl2, and ISG family genes
in monocytes of HIV (+) donors.
Spearman ranked correlation matrix of clinical parameters (brown), p53 (pink),
Bcl2 (blue), and ISG (green) family genes, and constitutive/induced apoptosis
(purple). Spearman test (two-tailed, unadjusted) with P < 0.05 considered
significant (bolded/red) and Spearman Rho is displayed. (n = 30).

load, CD4 count, and gene expression variables could generate a model for the
distribution of constitutive and induced apoptosis responses observed in HIVinfected patients. The adjusted R-squared rank method identified IFI27, IFITM2,
Rb1, and Bcl2 expression as the best model to describe variance in constitutive
apoptosis (P = 3.77 10-5, adjusted-R2 = 0.5983) (Table 2.5, Figure 2.15A). A
reduction of this model showed the key variables were IFI27 and Bcl2,
accounting for 96.4% of the adjusted R-squared. For oxidative stress-induced
apoptosis, the model system identified log viral load, IFITM2, Rb1, and Bax
expression (P = 5.59 10-5, adjusted-R2 = 0.5996) (Table 2.5, Figure 2.15B), with
log viral load and Rb1 expression representing 83.1% of the adjusted R-squared.
Taken together, the shift in functional monocyte apoptosis observed with
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increasing viral load was associated with a multi-gene association including
changes in Rb1, ISG, and Bcl-2 expression.

Table 2.5: Multivariate analysis of monocyte apoptosis in HIV-1 viremic
patients.
Constitutive and induced multivariate monocyte apoptosis models with Rsquared, P value, and model gene/viral load components shown.
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Figure 2.15: Multivariate analysis of monocyte apoptosis in HIV-1 viremic
patients.
Top models generated showing (fitted) versus observed constitutive (A) and
induced (B) apoptosis by multivariate stepwise regression of clinical parameters
and apoptosis-gene expression.

2.4 Discussion, limitations, and future directions
Here we show for the first time that monocyte apoptosis is elevated in
patients with greater than 40,000 HIV-1 copies/mL and negatively associated
with CD4 count (Figure 2.10). Our data suggest that infection can modulate
monocyte/macrophage activation, indicated by changes in CD14++CD16+
monocytes and sCD163, yet does not result in a rise in apoptosis until higher
viral loads, clarifying conflicting reports of monocyte apoptosis in HIV and SIV
infection (70, 96, 99, 103-105, 131).

Although elevated monocyte type 1 ISG expression (140, 144, 147) and
monocyte/macrophage activation markers (30, 32, 40, 71, 73, 86, 91, 150, 151,
176, 177, 184, 185) have been described during HIV-1/SIV infection, the present
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study extends these findings to include elevated monocyte apoptosis at high viral
load in spite of active mechanisms of apoptosis resistance (i.e. Rb1 expression)
(105). Change in ISG expression and increasing sCD14 with viral load may
evidence increasing microbial translocation, as plasma LPS was associated with
plasma IFN-α in HIV-1 viremic patients (86) and may contribute to the shift in
monocyte ISG expression and apoptosis induction (209, 210).

Previous studies have demonstrated elevated sCD14 in multiple HIV (+)
cohorts (relative to HIV (-) controls) (86, 151, 177, 178, 211), and while we
demonstrate an association with viral load and CD4 count (Figure 2.11C and
2.12), we do not detect a significant difference between our HIV (-) and HIV (+)
group (Figure 2.11A), which may reflect differences in sample size and the
clinical characteristic of our HIV (+) cohort. Interestingly, others have observed
biphasic CD163 expression on CD14++CD16+ monocyte subset relative to CD4
count (negative correlation below, positive correlation above 500 cells/mm 3) (31).
Although we did not measure cell-associated CD163 expression, we observed a
negative trend of CD4 count with sCD163, as well as a strong negative
correlation of CD4 count and sCD14 in patients below 500 cells/ mm3, supporting
these observations (Figure 2.12B). Based on these findings, we would expect
that the reversal of monocyte/macrophage activation markers upon ARTmediated suppression may vary qualitatively and temporally. This is supported by
ART-mediated resolution of Rb1 protein expression (105), decreases in the
CD14++CD16+ subset with treatment in early infection (177), persistence of
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plasma sCD14 (177-179), and partial, but incomplete resolution of plasma
sCD163 (150, 176, 177, 179). Longitudinal studies will be needed to establish the
relationship between monocyte/macrophage activation, infection stage, and ARTmediated viral suppression (Chapter 3).

In addition to the primary findings per impact of viral load, multivariable
analysis highlighted candidate ISG and Bcl2 genes as potential contributors to
the functional apoptosis shift when added to rising viral load (Table 2.5, Figure
2.15). Members of the ISG12 family (189, 190) examined here, including IFI6
(191, 192), IFI27 (193), and IFITM2 (194), have described apoptosis-regulation
functions. Of interest, IFITM2 was the only gene associated with apoptosis
outcome at the single gene level (Figure 2.14) and IFITM2 and Rb1 were present
in both models (Table 2.5, Figure 2.15), supporting specific candidate roles of
these genes as determinant of monocyte apoptosis in HIV-infected patients. The
impact of HIV-1 on Bcl2 family-mediated apoptosis in the CD4 compartment is
also well described (Reviewed in (22)), and the effect on non-CD4 cell types,
namely CD8 T-cells (212), dendritic cells (100), and now monocytes, suggests a
global impact of HIV-1 viremia and immune activation on Bcl2-mediated
apoptosis regulation. In addition, while Rb1 can override p53-mediated apoptosis
induction in vitro (203), it remains to be determined whether Bax and ISG12
family expression can override anti-apoptotic Rb1 expression as suggested by
our data. The multiple genes measured ex vivo as contributing to apoptosis
regulation makes it highly unlikely the functional phenotype can be accounted by
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any one gene. However, future work should determine how the described proapoptotic (IFI27, IFITM2, Bax) and anti-apoptotic (IFI6, Rb1, Bcl2) proteins exert
regulation of apoptosis when co-expressed/knocked down to defining overall
dominance or additive effects.

Our data do not address the potential impact of age and gender on
monocyte apoptosis (150, 151, 213). Both HIV (-) and HIV (+) groups represent
similar gender (no more than 25% female) and age distributions, but our cohort is
limited in the representation of females and elderly individuals (Table 2.3). Future
studies will need to address the impact of age and gender on monocyte
apoptosis and apoptosis-gene expression.

Although we interpret a direct role of target genes in apoptosis outcome, a
limitation of this study is the lack of single- and multi-gene overexpression/knockdown in monocytes to establish a role of target genes.
Mechanism and the impact of target gene over-expression on apoptosis outcome
are the primary objectives addressed in chapter 4. Also, while we focused on the
relationship between apoptosis and the expression of apoptosis-regulatory gene
families within monocytes (p53, ISG, Bcl2), our data do not exclude contributions
by external mechanisms in vivo affecting total monocyte numbers such as de
novo production/turnover described in SIV NHP models (70, 71) or external
pressures such as elevated soluble-TRAIL (99, 112) and increased TRAILmediated apoptosis (96, 107, 109, 113).
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In summary, we establish a shift in monocyte apoptosis and gene
expression in association with high HIV-1 viral load and low CD4 count, which
may bear on mechanisms for immunodeficiency, HIV replication, and/or HIV
reservoir retention during HIV-1 infection in vivo.

2.5 Materials

2.5.1 Pilot RNA sequencing and analysis
Aphaeresis material was obtained from HIV-seronegative (n=2) and HIVseropositive donors (n=4), and monocytes and CD4 T-cells were isolated by the
University of Pennsylvania Human Immunology Core (HIC) using the RosettaSep
kits from Stem Cell Technologies. RNA from purified CD4 T-cells and monocytes
from pilot cohort (Table 2.1) was obtained by trizol isolation (Sigma) and pooled
per group for analysis. Samples were Poly-A purified for mRNA and fragmented,
cDNA was synthesized, and 175-225 base pair cDNAs were purified from
agarose gel and sequenced in 36 base pair reads using the Illumina Genome
Analyzer II platform. Analysis included read filtering (removing rRNA and
mitochondrial reads) and alignment to genome and a custom-built transcription.
The CD4 T-cell expression profile was not available in the HVL group due to low
CD4 T-cell recovery.
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2.5.2 Donor population
HIV-1 seropositive donors (n = 35, 11.4% female, median age = 43.0
years) were recruited from the Hospital of the University of Philadelphia (HUP)
and Philadelphia Field Initiating Group for HIV-1 Trials (FIGHT) and were not on
therapy at the time of the single draw. Viremic patients showed a broad spectrum
of viremia (viral load range: 2,243-1,359,041 copies/mL; CD4 range 7-801
cells/mm3) (Table 2.7). Viral load and CD4 count are reported from the most
recent clinical visit (at most 3 months). HIV-1 seronegative donors (n = 33, 24.2%
female, median age = 43.5 years) were recruited from the University of
Pennsylvania Human Immunology Core and the Wistar Donors Program (Table
2.8). Assays data showing less than the total recruited HIV (-) or HIV (+)
population reflect limited patient material. All participants provided informed
consent prior to blood draw, and all protocols were approved by the institutional
review boards of the National Institutes of Health and The Wistar Institute.

2.5.3 Monocyte and CD4 T-cell isolation and characterization
Heparinized blood (70-200 mL) was processed within 1-3 hours of draw.
PBMC and plasma samples were obtained using Ficoll-Paque (Amersham
Pharmacia Biotech) gradient separation. HIV (-) and HIV (+) donor CD4 T-cells
were obtained from the University of Pennsylvania's Center for AIDS Research
Human Immunology Core obtained by Rosette Sep (Stemcell Technologies)
isolation from leukapheresis-PBMC. Monocytes were isolated by negative
selection using the Monocyte Isolation Kit II (Miltenyi Biotec, 139-091-153) with a
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mean biological purity greater than 85%. PBMC and isolated monocytes from
each sample were stained with CD4-V450, CD14-APC, CD16-APCH7, CD3PerCPCy5.5, and CD8-FITC for determination of purity, T-cell subsets, and
monocyte subsets. All flow cytometry antibodies were purchased from BD
Biosciences and used per the manufacturer’s instructions.

2.5.4 Plasma monocyte/macrophage activation markers
HIV (-) and HIV (+) plasma samples were assayed by ELISA (enzymelinked immunosorbent assay) for sCD14 (R&D Systems) and sCD163 (Trillium
Diagnostics), using 1:500 dilutions, according to the manufacturers’ instructions.
Plates were read on a BioTek Synergy HT microplate reader at 450 nm with the
appropriate wavelength corrections.

2.5.5 Quantitative real-time PCR
Total RNA was isolated from 2-5 million cells using the RNeasy Plus II Kit
(Qiagen) per the manufacturer’s protocol. Up to 250 ng of RNA was used with
the iScript cDNA synthesis kit (BioRad) as instructed. Quantitative real-time PCR
was performed in a 20 μL reaction using Power SYBR Green PCR Master Mix
(Life Technologies) and custom designed primers (Inegrated DNA Technologies)
(Table 2.9) using the AB 7000 Sequence Detection System. The QuantumRNA
Universal 18s Internal Standard (Ambion) was used due to its robust and
consistent expression across all samples. All primer sets were assayed by serial
dilution PCR across multiple donors to allow for absolute RNA quantification by
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the standard curve method. The mean of three replicates of each primer-sample
pair was input in the standard curve method and normalized to the sample’s 18s
value to generate an absolute RNA expression units value. (Expression units
defined as relative expression value to 18s after standardization.)

2.5.6 Apoptosis induction assay
Purified monocytes and CD4 T-cells were incubated overnight (18-22
hours) in non-adherent conditions (monocytes in Teflon pots to prevent
attachment) in the presence of RPMI 1680 media with 1% Penicillin/Streptomycin
(Corning), 1% L-Glutamine (Corning), and 10% Human Serum (Gemini BioProducts) with or without the addition of 20 μM CdCl2 (Sigma). All staining was
performed at room temperature (22°C). Between 500,000 and 1 million cells
were washed and incubated with FACS wash (DPBS (Life Technologies)
containing 3 mM NaN3 (Fisher), 1% Bovine Serum Albumin (Sigma), 5%Human
Serum (Gemini Bio-Products)) as an Fc-receptor block. Cells were stained with
CD3-Pacific Blue, CD14-APC and 7-aminoactinomycin D for 15 minutes. Cell
fixation/permeabilization was performed using the BD Cytofix/Cytoperm kit per
the manufacturer’s instructions and washed in 1 PermWash buffer. Cells were
then stained with anti-active caspase 3-PE (BD Biosciences), washed, and
resuspended in 300 μL 1 PermWash buffer. Apoptosis was also assayed at
baseline isolation in select samples. Up to 100,000 events were analyzed on a
14-color LSR II (BD Biosciences).
63

2.5.7 Flow cytometry gating and analysis
Flow cytometry data analysis was performed with FlowJo software
(TreeStar) (Figure 2.9). Singlets were gated using forward scatter height and
area. Live cells were gated, excluding debris and aggregates, with forward and
side scatter. To characterize monocyte subsets in PBMC, monocytes were gated
based on distinct forward and side scatter parameters and then CD14 + or CD16+
cells within this population. Monocytes were then divided into classical
(CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++)
subsets. In the apoptosis analysis, all events were gated on singlets, intact cells,
and either lymphocyte or monocyte forward/side scatter parameters. Cells were
analyzed using 7-AAD and caspase-3, and all cells in the early apoptotic and late
apoptotic quadrants were counted when determining the percent of apoptotic
cells within the population.

2.5.8 Statistical analysis
All dot, box and whisker, and scatter plots were constructed and
statistically tested using Prism 4 (GraphPad, La Jolla, CA). All group-wise
comparisons were performed using Mann-Whitney test with p-value displayed.
Correlations between two variables were performed using Spearman’s
Correlation (Rho) test with P and Rho (noted as R) values displayed. All tests
were two-sided and P < 0.05 was considered significant. The Spearman
correlation matrix was created with JMP10 software. Based on the analysis of the
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primary variable (monocyte apoptosis), HIV (+) patient measured variables are
presented below and above a viral load cutoff of 40,000 copies/mL (Log104.60).

2.5.9 Multivariate linear regression modeling
A stepwise multiple linear regression analysis was performed to model
constitutive and induced apoptosis using the combination of clinical and gene
expression variables. We conducted log transformation on the independent
variables and confirmed lack of multi-co-linearity in the final models within
independent variables by means of the variance inflation factor (VIF). The Cook’s
distance was used in outlier detection and removal of each independent model.
The model selection package “leaps” (Lumley and Miller 2009) in R was utilized
to identify the best subset of clinical/gene expression parameters that predicted
constitutive and induced apoptosis in the linear regression. The regsubsets
function within “leaps” was used to find the best subset of predictive parameters.
The adjusted R-squared statistic was used as the criterion for selecting the best
model with four or less variables per total input variable size. Various diagnostic
plots were used to check the assumptions for the multiple linear regressions
(data not shown). Q-Q plot was used to examine normality. Residuals plot was
used to examine the equal variance assumption.
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3.1 Introduction
Persistent immune activation during HIV-1 infection is associated with
disease progression and sub-optimal immune recovery after ART (16, 23-25).
Ongoing viremia has been noted to promote a state of innate immune activation
inclusive of changes in natural killer cells (179) and monocytes/macrophages.
Activation of monocytes and macrophages has been noted as a potentially major
source of inflammation due to mechanisms of activation that may not be fully
reversed during ART (80, 86, 91, 150, 174, 176-179) (Reviewed in Section 1.5).

During viremia, the CD14++CD16+ intermediate monocyte subset is
expanded in both HIV-1 (32, 34-36) and SIV infection (30) and associated with
HIV pathogenesis (32, 47, 150, 180). The significance of this subset as a
potential indicator of long-term inflammation is supported by similar elevations
described in patients with cardiovascular disease (35, 180). Soluble biomarkers
of monocyte/macrophage activation are also well-characterized in HIV disease,
including sCD14 and sCD163. Elevated sCD14 has been described as a marker
of HIV-associated microbial translocation and increases in plasma LPS (86, 152,
185). Cell-associated CD163 expression and shedding (as sCD163) from
monocytes and macrophages is also elevated during HIV/SIV infection (31, 69,
71, 177) and associated with both cardiac and CNS pathology (36, 71, 80, 176,
184). The relationship between innate and adaptive activation during viremia and
the expected decrease of both on ART raises the hypothesis that reduction in T-
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cell activation would be associated with reduction in monocyte and macrophage
activation.

ART-mediated resolution of monocyte/macrophage activation has become
a growing area of focus due the relationship with metabolic disease and retention
of immune activation during HIV infection (36, 47, 150, 176, 184) (Table 3.1). The
CD14++CD16+ intermediate monocyte subset is decreased in patients treated
during early infection, but not chronic infection (177); cross-sectional comparison
has demonstrated that suppressed patients reach comparable levels to HIV (-)
donors (35). Interestingly, a reduction of the intermediate monocyte subset was

Table 3.1: Monocyte/macrophage activation during ART.
Study type, sCD14 impact, sCD163 impact, and other findings shown for reports
on monocyte/macrophage activation during ART.
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noted in patients with CD4 counts below 350 cells/mm3, but this study did not
examine other markers of T-cell or monocyte/macrophage activation (34).
Plasma sCD163 was reduced to normal levels in patients treated during early
infection, but not those treated at later stages (177). Additionally, cross-sectional
studies suggest sCD163 does not reach normal levels with viremic suppression
(150, 176, 177, 179). Plasma sCD14 is even less plastic. Longitudinal studies
have found elevated sCD14 levels persist despite viral suppression (86, 174,
177) and are only partially resolved after extended ART (174, 175). Crosssectional comparisons have demonstrated that sCD14 levels are not resolved to
normal levels in ART-treated patients (91, 152, 174, 178, 179).

A major component of monocyte/macrophage activation during viremia is
the upregulation of ISG expression (Reviewed in Section 1.4). Among these,
CD169 (Sialoadhesin, SN, SIGLEC1) is a surface-expressed ISG (IFN-α, IFN-γ
inducible) on monocytes, macrophages, and dendritic cells that is highly
expressed during HIV-1 infection (143, 154, 156) and other inflammatory
diseases (155, 157). CD169 can also facilitate trans-infection of target cells by
both monocytes and dendritic cells (156, 158, 159). Its expression can be
reversed with viral suppression after ART in SIV infection (160).

Studies have suggested that CCR5 antagonism may improve resolution of
T-cell activation during ART initiation (temporary advantage) (214, 215) yet data
is not uniform across intensification studies to date (215-218). Regarding
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monocyte/macrophage activation, Maraviroc-inclusive ART has yielded mixed
results regarding sCD14 resolution (216, 217, 219, 220) (Table 3.2). Some

Table 3.2: Monocyte/macrophage activation during non-standard ART.
Study type, sCD14 impact, sCD163 impact, and other findings shown for reports
on monocyte/macrophage activation during non-standard ART (Maraviroc,
Elvitegravir, Rosuvastatin).

variability may be attributed to cohort and therapy differences, as intensification
studies often target immunological non-responders (215, 217, 218). Taken
together, the immunological impact of a Maraviroc-inclusive regimen in patients
initiating ART from advanced infection has not been described. Although addition
of CCR5 antagonism (Maraviroc) did not impact the degree of CD4 recovery in
patients starting with nadir CD4 counts in the parent study (221), we hypothesize
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it may reduce monocyte/macrophage activation by inhibiting
monocyte/macrophage recruitment and viral-CCR5 interactions (222, 223).

In this chapter, we describe the changes in biomarkers of monocyte and
macrophage activation and the impact of CCR5 antagonism in patients initiating
ART in advanced disease (CD4 count below 100 cells/mm3). Our primary
analysis aimed at determining the degree and kinetics of reversal of
monocyte/macrophage activation with respect to T-cell activation, while
secondary analysis addressed the impact of CCR5 antagonism on
monocyte/macrophage activation. With 24 weeks of suppressive ART, we
observed a differential reversal of biomarkers of monocyte/macrophage
activation. Apart from increases in the percentage of peripheral blood monocytes
expressing CCR5, no Maraviroc-mediated effects on monocyte/macrophage
activation markers with ART were noted.

3.2 Antiretroviral therapy in HIV-1 infected individuals with CD4 count
below 100 cells/mm3 results in differential reversal of
monocyte/macrophage activation

3.2.1 Study cohort and baseline characteristics
Patients were recruited in the CADIRIS (CCR5 antagonism to decrease
the incidence of immune reconstitution inflammatory syndrome) study examining
the impact of Maraviroc-inclusive ART on IRIS incidence in low CD4 count HIV-1
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patients initiating ART between five study sites in Mexico and one in South Africa
(221). Patients received placebo or Maraviroc (600 mg) in addition to a
background of Efavirenz (EFV, 600 mg), Tenofovir, (TDF, 300 mg), and
Emtricitabine, (FTC, 200 mg), and plasma and PBMC were isolated from whole
blood at 0 (pre-ART), 12, and 24 weeks. Archived plasma and PBMC were
analyzed from 65 patients from the South Africa site that were virologically
suppressed at week 24 (defined as viral load less than 400 HIV-1 RNA
copies/mL). Inclusion criteria of the parent study required a baseline CD4 count
of less than or equal to 100 CD4 T-cells/mm3, allowing us to investigate the
impact of ART-mediated suppression on monocyte/macrophage activation
biomarkers in advanced HIV-1 infection. Consistent with the parent study, no
difference in gender, age, and baseline clinical metrics (viral load, CD4 count,
CD8 count) was observed between the placebo and Maraviroc groups in the substudy (Table 4.3). Baseline T-cell and monocyte/macrophage activation markers
were also not different between groups.
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Table 3.3: Cohort baseline characteristics.
Demographic, clinical, and T-cell and monocyte/macrophage activation baseline
metrics are shown for ART + Placebo group, ART + Maraviroc group, and total
ART cohort. P values were calculated by Mann-Whitney test for all comparisons,
excluding gender which was calculated by Fisher’s exact test.
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3.2.2 Change in T-cell count and biomarkers of T-cell activation
Median CD4 count increased from 46 and 41 (placebo and Maraviroc
group) to 149 and 177 cells/mm3 during 24 weeks ART (P < 0.0001 for both
groups, P = 0.5710 between groups at week 24) (Figure 3.1A). The parent study
and others have observed higher CD8 counts in Maraviroc groups during ART
(217, 221), and the sub-study observed a similar trend (P = 0.0579, week 24)
(Figure 3.1B). As these patients initiated therapy from advanced infection, we did

Figure 3.1: CD4 and CD8 T-cell count during ART.
Shown are placebo (blue) versus Maraviroc (red) group CD4 count (A) and CD8
count (B) absolute and relative to baseline change. Median and interquartile
range (IQR) are displayed, and only patients with all time points are shown.
Mann Whitney comparison between groups was performed at each time point
with P < 0.05 considered significant and displayed. Longitudinally, Friedman test
and post hoc Dunn test were performed with P < 0.05 considered significant and
displayed.
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not expect uniform decreases in T-cell activation markers by week 24 (24, 25).
However, T-cell activation, measured by CD38+, HLA-DR+ T-cells, was uniformly
reduced in both CD4 and CD8 T-cells in both groups by week 24 (P < 0.0001 for
CD4 and CD8) (Figure 3.2, 3.3A, B). At week 24, we detected a small but
significant difference in CD38+, HLA-DR+ CD4 T-cells (3.555% in placebo versus
2.620% in Maraviroc, P = 0.0072, Figure 3.3A). The percent of CD4 and CD8 Tcells expressing CD38 was also significantly reduced in both arms (P < 0.001 for
CD4 and CD8) (Figure 3.3C, D). Independent of group, the percent of CD4 or
CD8 T-cells expressing CD38 or CD38 and HLA-DR was reduced by 49-70%
from baseline (Figure 3.3).

Figure 3.2: Representative T-cell activation biomarkers during ART.
Representative donor CD4 (top) and CD8 (bottom) T-cell expression of CD38 (xaxis) and HLA-DR (y-axis) during ART are shown.
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Figure 3.3: T-cell activation markers during ART.
Shown are placebo (blue) versus Maraviroc (red) group percent of CD38 +, HLADR+ CD4 T-cells (A), CD38+, HLA-DR+ CD8 T-cells (B), CD38+ CD4 T-cells (C),
and CD38+ CD8 T-cells (D) during ART absolute and relative to baseline change.
Median and interquartile range (IQR) are displayed, and only patients with all
time points are shown. Mann Whitney comparison between groups was
performed at each time point with P < 0.05 considered significant and displayed.
Longitudinally, Friedman test and post hoc Dunn test were performed with P <
0.05 considered significant and displayed.
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3.2.3 In vivo impact of Maraviroc on monocyte/macrophage activation
markers and T-cell and monocyte CCR5 expression
Markers of monocyte/macrophage activation were not significantly
different between groups (data not shown). We observed a higher percentage of
CCR5 expressing CD4 T-cells, CD8 T-cells, and monocytes in PBMC of the
Maraviroc group during ART (Figure 3.4), as evidence of therapy exposure and
as reported by others (217). We interpret this to reflect a lack of ligand-mediated
receptor internalization and/or lack of tissue migration of CCR5+ cells in the
Maraviroc group. As we did not detect an impact of Maraviroc on
monocyte/macrophage biomarkers of activation, from this point onwards, we
opted to analyze ART-mediated changes independent of study group.

Figure 3.4: Maraviroc-inclusive ART results in a greater percent of CCR5positive T-cells and monocytes in PBMC.
Shown are percent of CCR5-positive CD4 T-cells (A), CD8 T-cells (B), and total
monocytes (C) during ART in placebo (Pla) versus Maraviroc (Mvc) groups.
Mann Whitney comparison between groups was performed at each time point
with P < 0.05 considered significant and displayed.
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3.2.4 ART reduces cell-associated and soluble markers of
monocyte/macrophage activation
The reversal of cell-associated and soluble markers of
monocyte/macrophage activation is not well-described during ART in advanced
infection, and their potential reversal may inform prognosis of such cohorts, as
markers of monocyte/macrophage activation are associated with
pathogenesis/predict outcome (78, 80, 91, 92, 176, 180). Based on previous ART
studies (Reviewed in Section 1.5, Table 3.1), we predicted ART and viral
suppression will reduce the percent of the CD14++CD16+ intermediate
monocytes, the percent of CD163+ monocytes, and the level of plasma sCD163,
while plasma sCD14 will not change. Within total monocytes, the percent of
CD14++CD16+ intermediate monocytes (Figure 3.5) and CD163+ monocytes were

Figure 3.5: Representative change in monocyte subsets during ART.
Representative donor monocyte subsets during ART determined by CD14 (xaxis) and CD16 (y-axis). Subsets are defined as classical (CD14++CD16-),
intermediate (CD14++CD16+), and non-classical (CD14+CD16++) subsets.
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Figure 3.6: Monocyte/macrophage activation biomarkers during ART.
Shown are percent of intermediate monocytes (A), CD163-positive monocytes
(B), plasma sCD163 (C), and plasma sCD14 (D) absolute and relative to
baseline change. Longitudinal comparisons display median and interquartile
range with Tukey’s method using the Friedman test and Dunn post hoc test with
P < 0.05 considered significant and displayed.
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significantly reduced by week 24 (P < 0.0001 and P = 0.0004) with a relative
reduction of 61.96% and 55.54% from baseline (Figure 3.6A, B, Table 3.4).
Complete subset and subset activation markers are provided in Table 3.5. In
plasma, sCD163 was also significantly reduced at week 24 with a relative
reduction of 28.04% from baseline (P < 0.0001) (Figure 3.6C). Plasma sCD14
was significantly reduced by week 24 but with only a 14.70% reduction from
baseline (P = 0.0081) (Figure 3.6D). We show a reduction in both cell-associated
and soluble markers of monocyte/macrophage activation.

Table 3.4: Total monocyte activation markers.
Median and interquartile range are displayed. Values for week 12 and 24 are
displayed in red if decreased (P < 0.05) from Week 0. Friedman test and Dunn
post hoc test.
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Table 3.5: Monocyte subsets and subset activation markers.
Median and interquartile range are displayed. Values for week 12 and 24 are
displayed in red if decreased (P < 0.05) from Week 0. Friedman test and Dunn
post hoc test.
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3.2.5 Reduction of markers of monocyte ISG expression
We also investigated the reversal of markers of ISG expression (CD169,
tetherin) as ISG expression in monocytes/macrophages may contribute to HIV-1
associated immune dysfunction (Reviewed in Section 1.4). CD169 was highly
expressed on total monocytes pre-ART and was reduced to marginal expression
after 12 weeks ART (P < 0.0001) (Figure 3.7A, Table 3.4). Tetherin expression
was also reduced by 24 weeks (P = 0.0153, 38.94% reduction) (Figure 3.7B,
Table 3.4). Both CD169 and tetherin expression were significantly reduced in all
monocyte subsets at weeks 12 and 24 (Table 3.5). The rapid and near complete
reduction of monocyte CD169 expression stands out as a very early and
reversible marker of HIV-1 viremia, suggesting that control of viral replication
removes a major stimulus for monocyte ISG induction.

Figure 3.7: ART reduction of monocyte ISG markers.
Shown are the percent of CD169+ monocytes (A) and tetherin expression (B)
with representative donors (left), absolute values (middle), and change relative to
baseline (right) during 24 weeks ART. Longitudinal comparisons display median
and interquartile range with Tukey’s method using the Friedman test and Dunn
post hoc test with P < 0.05 considered significant and displayed.
83

3.2.6 Correlates of monocyte apoptosis resistance during ART
Previous findings have demonstrated that signaling through CCR5 (103,
105) and elevated intracellular monocyte zinc content (104) are mechanisms
associated with apoptosis resistance in monocytes from viremic HIV-1 patients.
To address the potential reversal of these mechanisms, we investigated
monocyte CCR5 expression and zinc content (Figure 3.8). As noted earlier, the
percent of monocytes expressing CCR5 was higher in the Maraviroc group
during therapy (Figure 3.8B); however, no difference in zinc content was noted

Figure 3.8: Correlates of monocyte apoptosis resistance during ART.
Representative (Maraviroc patient) (A) and cohort (B) CCR5 expression during
24 weeks ART in placebo (Pla) and Maraviroc (Mvc) groups. Group comparisons
display median and interquartile range using the Mann Whitney test. Monocyte
zinc content (representative (C), relative value (D), relative change (E)) during 24
weeks ART. The dotted line (D, E) represents the MFI of the HIV (-) standard
repeated during each experiment. Longitudinal comparisons display median and
interquartile range using the Friedman test and Dunn post hoc test with P < 0.05
considered significant and displayed.
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between therapy groups (data not shown). Zinc content was decreased by 12
weeks in total monocytes (Figure 3.8D) and the classical subset, but was
unchanged in the intermediate and non-classical subset (Table 3.5). We interpret
ART may reduce the anti-apoptotic impact of monocyte zinc content, by
reduction within classical monocytes or reduction of the size of the intermediate
subset.

3.2.7 Correlates in the change of T-cell and monocyte/macrophage
activation biomarkers
We last examined the association of change within the activation markers
examined and CD4 count to determine which monocyte/macrophage markers
would inform the resolution of T-cell activation and CD4 reconstitution (Figure
3.9, total monocytes; Figure 3.10, monocyte subsets). Interestingly, the change

Figure 3.9: Correlation of change in T-cell and total monocyte/macrophage
activation biomarkers.
Spearman rho is displayed with P < 0.05 considered significant and displayed in
green, P < 0.01 in blue, and P < 0.001 in red. Median 24 week change is shown
in column one parentheses.
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in CD4 count was negatively associated with the change in CD163+ total
monocytes, suggesting the reversal of CD163 expression may be useful as a
monocyte benchmark of immune reconstitution. Data show that the change in
CD8 activation (CD38+, HLA-DR+) was associated with change in CD169 and
tetherin expression on total monocytes. Interestingly, CD4 or CD8 T-cell
activation (CD38+, HLA-DR+) change was not associated with changes in the
CD14++CD16+ intermediate subset, CD163 expression, or plasma sCD14. These
data suggest decreases in markers of T-cell activation, observed after viremic
suppression, are mirrored by monocyte markers of ISG expression (CD169,
tetherin) as opposed to those associated with inflammatory cascades.

Figure 3.10: Correlation of change in T-cell and monocyte
subset/macrophage activation biomarkers.
Spearman rho is displayed with P < 0.05 considered significant and displayed in
green, P < 0.01 in blue, and P < 0.001 in red. Median 24 week change is shown
in column one parentheses.
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3.3 Discussion, limitations, and future directions
Our data indicate that ART-mediated viral suppression in advanced HIV-1
infection results in differential reduction of monocyte/macrophage activation
markers relative to T-cell activation markers. Additionally, CCR5 antagonism
(Maraviroc) did not impact markers of monocyte and macrophage activation
beyond use of ART alone. The latter indicates suppression of viral replication is
dominant over CCR5 antagonism in determining change in innate immune
activation. However, as we did not examine activation in tissue, as done by other
studies (217), we cannot exclude a long-term impact of CCR5 antagonism on
tissue damage, repair, and reconstitution, as should be a focus of future studies.
Although other studies have addressed retention of activation in monocyte
subsets after viral suppression, our study reports for the first time the differential
changes observed when ART is initiated in advanced infection.

While we generally observed decreases across biomarkers of monocyte
and macrophage activation with viral suppression, different degrees of change
were observed between markers. At one end, monocyte CD169 expression was
greatly reduced by 12 weeks (median 97.94% relative reduction), representing
the marker with the closest alignment to control of viral replication. Others have
described a correlation of CD169 expression and viral load (156); however, we
did not detect this association, possibly due to the narrow viral load distribution of
our cohort (Log viral load (copies/mL): 4.378–6.383). CD169 expression is
reversed with ART in the SIV macaque model (160). Our data support this finding
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in HIV-1 patients initiating ART during advanced infection. The level of
CD14++CD16+ (intermediate) monocytes was significantly reduced by greater
than 50% by week 24 (Figure 3.6), aligning with similar ART-mediated decreases
(34, 35).

Unexpectedly, CD163 monocyte expression was not correlated with
sCD163. As follows, monocyte CD163 expression may represent independent
immunological pressures from those driving receptor shedding. Interestingly, our
measurement of CD163 expression may under-represent in vivo expression
levels as others have described lower values on PBMC as compared to whole
blood staining (CD163 antibody clone GHI/61 used both here and referenced
studies) (31, 224). Our prior work has described the impact of viremia on
monocyte ISG expression and apoptotic regulation (103-105, 225). Our data
support the relationship between viral suppression and an immediate reduction in
ISG expression in contrast to the change in markers of TLR-mediated activation.
Plasma sCD14 was the least plastic biomarker over 24 weeks ART, supporting
previous studies (86, 174, 175, 177, 179). Our data suggest sCD14 is stable in
the majority of patients during ART treatment in advanced HIV-1 infection.

The absence of age, gender, and geographically-matched HIVseronegative donors limits our ability to interpret resolution to normal levels.
However, this does not affect our ability to interpret what variables best reflect
changes in T-cell activation, viral suppression, and immune reconstitution.
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Second, the absence of functional responses limits assessment regarding
retention of plasma sCD14 and altered TLR responses. Third, data analysis on
patients with viral suppression by week 24 and complete datasets (week 0, 12,
24) may introduce selection bias limiting our interpretation to patients with
favorable clinical outcomes. Finally, due to the use of cryopreserved PBMC and
the absence of gene expression data, we are unable to directly measure
monocyte apoptosis and are therefore limited to describing changes in variables
that are expect to reflect apoptosis resistance mechanisms (Figure 3.8) (103105).

In summary, we describe a spectrum of reduction of indicators of
monocyte/macrophage activation in advanced HIV-1 infection during 24 weeks
ART. We also differentiate activation variables closely associated with control of
viral replication (CD169), CD4 reconstitution (CD163), and those showing a
strong relationship with decreased CD8 T-cell activation (CD169 and tetherin).
The lack of greater change in both sCD14 and sCD163 after ART suggests that
microbial translocation and associated activation may be of greater concern in
advanced infection despite viral suppression.
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3.4 Materials

3.4.1 Donor population
HIV-1 seropositive patients (n = 65; 56.9% female; median age = 38
years) were recruited as part of sub-study B (South Africa study site) within the
CADIRIS parent study (221). Inclusion criteria targeted ART-naïve individuals
with a CD4 count less than 100 cells/mm3 (Table 3.3). Patient data with failure to
suppress viral load below 400 RNA copies/mL by week 24 were excluded from
analysis. Patients received placebo or Maraviroc (600 mg) in addition to a
background of Efavirenz (EFV, 600 mg), Tenofovir, (TDF, 300 mg), and
Emtricitabine, (FTC, 200 mg), and plasma and PBMC were isolated from whole
blood at 0 (pre-ART), 12, and 24 weeks. Data showing less than the total cohort
reflect unavailable patient material or limited assay capacity. Figures expressing
paired, longitudinal data (Figure 3.1, 3.3, 3.6, 3.7, 3.8) include patients with only
complete data (0, 12, and 24 weeks). All participants produced informed consent
in accordance with clinical trial NCT 00988780.

3.4.2 T-cell and monocyte flow cytometry
T-cell activation and monocyte activation were characterized by flow
cytometry analysis of PBMC samples (Table 3.6). T-cell activation markers were
measured in PBMC were thawed and stained with CD3-V450, CD38-APC, HLADR-APCH7, CD4-PerCPCy5.5, CCR5-PE, and CD8-FITC. Monocyte activation
and ISG expression markers were measured in PBMC with CD3-V450
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Table 3.6: PBMC Flow cytometry panel.
(exclusion), CD14-APC, CD16-APCH7, CCR5-PerCPCy5.5, CD169-PE, and
CD163-FITC as well as CD14-V450, CD16-APCH7, CD3-PerCPCy5.5
(exclusion), CD317-PE (Tetherin), and CCR5-FITC. Cell type-matched gates
(CD3+ for T-cells, CD14, CD16 combined gate for monocytes) isotypes were
used for negative/positive gating. Aqua Live/Dead (Life Technologies) was used
for dead cell exclusion. All flow cytometry antibodies were purchased from BD
Biosciences (with the exception of CD169-PE from eBioscience and CD317-PE
from BioLegend) and used per the manufacturers’ instructions. T-cells were
gated on singlets using forward scatter height and area, lymphoid scatter profile,
CD3+ cells, followed by CD4+ and CD8+ T-cells (Figure 3.11A). Monocytes were
gated on singlets, monocyte scatter profile, CD3 exclusion, total monocytes
(CD14, CD16 combined gate), and the monocyte subsets, classical monocytes
(CD14++CD16-), intermediate monocytes (CD14++CD16+), and non-classical
monocytes (CD14+CD16++) (Figure 3.11B, C). All figures depicting monocyte
activation markers represent the total monocyte population. Flow cytometry data
91

Figure 3.11: Flow cytometry gating.
Representative T-cell (A) and monocyte (B) flow cytometry gating strategy.
Target molecule expression was evaluated on CD4 and CD8 subsets for T-cells
(A) and total monocytes and classic, intermediate, and non-classical subsets for
monocytes (B-C).

analysis and images was generated with FlowJo software (TreeStar). All flow
cytometry data reported display percent of positive cells relative to the parent
population with the exception of tetherin (MFI) (Figure 3.7B) and zinc content
(Figure 3.8C-E).

3.4.3 Monocyte zinc content
Monocyte zinc content was determined in PBMC using CD11b-V450,
CD14-APC, CD16-APCH7, CD3-PerCPCy5.5 (exclusion), and 5 μM Newport
Green DCF Diacetate cell permeate zinc indicator (Life Technologies). Control
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PBMC from the same HIV-seronegative donor was thawed each time the assay
was performed and stained in parallel as a standard to which each sample was
normalized. The MFI (mean fluorescence intensity) of each sample was divided
by the MFI of the control donor in order to calculate the relative zinc content
(Figure 3.8C).

3.4.4 Plasma activation markers
Plasma samples were assayed by ELISA for sCD14 (R&D Systems) and
sCD163 (Trillium Diagnostics), using 1:500 dilutions, according to the
manufacturers’ instructions. Plates were read on a BioTek Synergy HT
microplate reader at 450 nm with the appropriate wavelength corrections.

3.4.5 Statistical analysis
All dot and box-and-whisker plots were generated and statistically tested
using Prism 6 (GraphPad, La Jolla, CA) and two-group longitudinal graphs
(Figure 3.1, 3.3) were generated using Microsoft Excel. All graphical plots show
median and interquartile range and box-and-whisker plots are displayed using
Tukey’s method. Relative change was calculated as percent change relative to
week 0 (Pre-ART). Group comparisons at the same time point were performed
using the Mann-Whitney test (two-tailed). Longitudinal comparisons were
performed using the Friedman test with the Dunn post hoc test between time
points. P values less than 0.05 were considered significant and are displayed.
Correlation of T-cell and monocyte/macrophage biomarker change (Week 2493

Week 0) (Figure 3.9, 3.10) was calculated with Spearman’s test (two-tailed) with
rho displayed and P < 0.05 in green, P < 0.01 in blue, and P < 0.001 in red.
Correlation matrices (Figure 3.9, 3.10) were not adjusted for multiple testing.
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CHAPTER 4: Mechanistic investigation of HIV-1 induced
monocyte apoptosis resistance: Impact of ISG12 family
gene expression

4.1 Introduction
4.1.1 Background
4.1.2 Rationale
4.2 IFI6 and IFI27 ectopic expression system and induction in vitro
4.3 Impact of IFI27 over-expression on apoptosis in Monomac1 cell line
4.4 Discussion, limitations, and future directions
4.5 Materials
4.5.1 Generation of inducible expression Monomac1 cell lines
4.5.2 Apoptosis induction in transduced Monomac1 cell lines
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4.1 Introduction

4.1.1 Background
Pilot RNA sequencing and RT-PCR follow-up highlighted members of the
ISG12 gene family as candidate genes that may contribute to the regulation of
monocyte apoptosis during HIV-1 infection (Reviewed in (189, 190)). Within this
family, expression of IFI6, IFI27, and IFITM2 was elevated in HIV (+) individuals
(compared to HIV (-) individuals) and associated with viral load (Table 2.4, Figure
2.13).

The ISG12/FAM14 family consists of low molecular weight hydrophobic
(often membrane-associated) proteins highly induced by interferons and during
viral infection (189, 190, 193, 195, 226, 227). IFI6/G1P3 is a 13 kDa protein with
known anti-apoptotic properties (190). Specifically, IFI6 is upregulated in
myeloma and gastric cancer cell lines and facilitates apoptosis resistance to
intrinsic, mitochondrial-mediated apoptosis (191, 192). Upregulation of IFI6
during Dengue virus infection of endothelial cells is associated with protection
from infection-induced apoptosis (228).

IFI27 is a 12 kDa hydrophobic protein (encoded by ISG12a/FAM14D) that
localizes to the mitochondrial membrane and facilities mitochondrial-mediated
pro-apoptotic impact (190, 193), similar to mouse ISG12b2 (195). IFI27
expression is upregulated during various viral infections (VSV, CMV, HCV, RSV,
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HIV) (140, 193, 195, 226, 227), and may predict treatment outcome during HCV
infection (229, 230). Similar to IFI27, IFITM2 has also be described as a proapoptotic ISG12 member (194). Also members of the ISG12/FAM14 family, the
IFITM proteins (IFITM1-3) and the ubiquitin-like ISG15 protein have
demonstrated anti-viral and anti-HIV properties, but are beyond the focus of
these studies (170, 196, 231-233).

4.1.2 Rationale
An increase in monocyte apoptosis with increasing viral load paired was
paired with elevated ISG expression (Chapter 2). The latter prompted an
investigation of underlying mechanistic pathways that may account for this effect.
This chapter will investigate the independent role of ISG12 family gene
expression on monocyte apoptosis sensitivity. Based on the observation that
ISG12 family expression was elevated in HIV (+) patients with elevated monocyte
apoptosis ex vivo (Chapter 2), we tested the hypothesis that elevated proapoptotic ISG12 family gene expression would be sufficient to increase apoptosis
sensitivity in a monocytic cell line. Specifically, we tested if induced expression of
IFI6 or IFI27 could modulate monocyte apoptosis outcomes. Work described in
this chapter includes the design and implementation of an inducible gene
expression system to gauge the impact of pro- and anti-apoptotic ISG12
members on monocyte apoptosis.
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4.2 IFI6 and IFI27 ectopic expression system and induction in vitro
We tested the hypothesis that ectopic expression of IFI6 or IFI27 would
impact apoptosis outcome in a monocytic cell line. Based on the described
apoptotic functions of these proteins (Section 4.1), our hypothesis predicts
expression of IFI6 would protect cells from apoptosis and expression of IFI27
would sensitize cells to apoptosis.

To investigate our hypothesis, we generated stably transduced cell lines
expressing each of the genes of interest under an inducible promoter. Three
splice variants of IFI6 have been described (189): the 130 amino acid IFI6a,
IFI6b with four additional amino acids at position 24, and IFI6 with 8 additional
amino acids at position 24; however, to our knowledge, no functional impact of
these variants has been described. IFI6a (130aa) was chosen based on template
availability. IFI27/ISG12 exists in four isoforms, the full length ISG12, a splice
variant lacking exon 2 designated ISG12-S, a three amino acid deleted variant
designated ISG12Δ, and the combined ISG12-SΔ (189, 234). We chose the full
length ISG12 based on template availability and because it retains both
transmembrane domains (189).

The Monomac1 (MM1) cell line, established from an acute monocytic
leukemia, was chosen for its ease of culture for flow cytometry applications,
functional capacity (produces TNF-α after LPS stimulation, data not shown), and
permissiveness to HIV-1 infection (235, 236). Cloning primers were engineered
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with 5’ BamHI and 3’ Nhe1 restriction sites and IFI6 and IFI27 gene fragments
were generated from commercial templates (Figure 4.1). A dual-transduction

Figure 4.1: IFI6 and IFI27 cloning primers.
Shown are BamHI (red) and NheI (green) restriction site-engineered primers for
the cloning of IFI6 and IFI27 gene fragments into delivery plasmid.
system was set up using the pLU-EF1aL-rtTA3-iCherry (“helper plasmid”) and
pLU-TREmin-MCS-pGFP (“transducing plasmid”) constructs in a VSV-delivery
system (Figure 4.2). The mCherry (under the IRES promoter) and eGFP (under
the hPGK promoter) provide fluorescent markers to sort and purify dualtransduced cells. The gene of interest is cloned into the transducing plasmid
downstream of the Tet-response element (TREmin) and requires both rtTA3,
constitutively produced from the helper plasmid, and exogenous Doxycycline
treatment to induce gene expression. Three transducing plasmids/viruses were
generated: TREmin-MCS-pGFP (no gene of interest control), TREmin-IFI699

pGFP, and TREmin-IFI27-pGFP, each to be co-transduced with the mCherry
helper virus.

Figure 4.2: Gene delivery plasmids.
Shown are plasmid maps for “helper plasmid” (red) and “transducing plasmid”
(green). rtTA3 gene product from “helper plasmid” and exogenous doxycyline
treatment are both required for gene expression from inducible promoter on
“transducing plasmid.”

We titrated the 3-day transduction capacity of each virus and found
greater than 90% transduction at 2.5 μL of each eGFP virus (MCS, IFI6, IFI27).
The mCherry helper virus had less separation and up to 23.7% transduction at 5
μL of virus (Figure 4.3A-B) (Virus treatment given at μL virus stock per 2 million
cells). We then examined the co-transduction efficiency of these viruses and
found 38.8-44.5% co-transduction (2.5 μL each GFP virus plus 5 μL rtTA3mCherry) (Figure 3.3C). We proceeded to sort two single transduced populations
(MCS-GFP alone and rtTA3-mCherry alone) as controls (i.e. compensation) and
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Figure 4.3: Single and co-transduction titrations.
(A-B) Single transduction titration (0-5 μL transducing virus) of control (MCSGFP), IFI6-GFP, IFI27-GFP, and rtTA3 transducing viruses. (C) Dualtransduction of rtTA3-mCherry (2.5 μL) and MCS-GFP (left), IFI6-GFP (center),
and IFI27-GFP (right). Plots show mCherry (x-axis) and GFP (y-axis)
fluorescence.

the three target co-transduced lines (Figure 4.4A-B). Although the cotransduction efficiency was much lower (5-7%) compared to the previous titration
(38-44%), we successfully purified all target cell lines. Sorted cells were
expanded by subsequent culture and archived as stock cultures. Cultures were
periodically restarted from stored stocks as we also noted that time in culture
resulted in eventual dilution of the transduced population (Figure 4.4C). This may
be the result of loss of reporter expression or outgrowth of a small population of
un-transduced contaminants.
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Figure 4.4: Dual-transduction and sorting.
(A) Single and dual-transduced cell line set up showing viruses used and cells
transduced/sorted. (B) Transduction efficiency and populations sorted. Dual
transduction (4, 5, 6) show GFP (x-axis) and mCherry (y-axis) fluorescence. (C)
Transduced stocks were periodically examined for reporter expression. Graph
shows the remained single or dual-transduced (by indicator) cells in active
culture.

We then tested for an apoptosis response in the Monomac1 cell line by
titrating apoptosis-inducing agents (independent of target gene induction).
Cadmium chloride (CdCl2), used as an oxidative stress inducer in primary
monocytes (103-105, 225), was titrated on the cell line. A target of 15% caspasepositive cells at 35 μM CdCl2 was chosen (Figure 4.5A) (n=3). The
topoisomerase II inhibitor, etoposide (237), was also evaluated and induced
apoptosis on this cell line (Figure 4.5B).
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Figure 4.5: Monomac1 apoptosis induction titration.
(A) Dose-response titration of CdCl2 treatment (μM) versus apoptosis induction
(measured by active caspase-3) (representative of n=3 replicates). (B) Doseresponse titration of etoposide treatment (μg/mL) versus apoptosis induction
(measured by active caspase-3) (representative of n=2 replicates).

4.3 Impact ofIFI6 and IFI27 over-expression on apoptosis in Monomac1 cell
line
We first confirmed specific gene induction by RT-PCR using a 24 hour, 01000 ng/mL doxycycline dose-response (Figure 4.6). Doxycycline did not induce
expression of off-target genes in any cell line, such as the Rb1 or the prototypic
ISG, Mx1, in any cell line (Figure 4.6A-B). IFI6 RNA expression peaked at 4.5
expression units in the IFI6 cell line (Figure 4.6C), comparable to HIV (+) RNA
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Figure 4.6: Monomac1 gene induction dose response.
Shown is Rb1 (A), Mx1 (B), IFI6 (C), and IFI27 (D) gene expression measured by
RT-PCR in transduced cell-lines treated with 0-1000 ng/mL doxycycline for 24
hours. Show are untransduced MM1 (blue), MCS-no gene control (red), IFI6transduced (green), and IFI27-transduced (purple) cell lines.

expression ex vivo (Table 2.4, Figure 2.13). IFI27 was robustly induced in its
specific cell line (Figure 4.6D), above 6000 units at 1000 ng/mL doxycycline,
again, comparable to ex vivo HIV (+) patient monocytes (Table 2.4, Figure 2.13)
and IFN-α treated HIV (-) monocytes in vitro (Figure 2.5). These data
demonstrate induction of specific genes of interest in the target cell lines. Based
on the ISG12 induction kinetics observed with IFN-α treatment (Figure 2.6) we
also conducted a time course of gene expression in our inducible cell lines (at
1000 ng/mL doxycycline) (Figure 4.7). Similar to IFN-α treatment in primary
monocytes, IFI6 expression peaked at 4 hours post induction in the inducible
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system and declined thereafter (Figure 4.7A). IFI27 expression exceeded 1000
expression units by 8 hours and remained elevated beyond 24 hours (Figure
4.7B). Based on induction optimization experiments, functional experiments were
carried out with 1 ng/mL doxycycline and 4-8 hours of post-induction gene
expression.

Figure 4.7: Monomac1 gene induction time course.
IFI6 (A) and IFI27 (B) cell lines were treated with 1000 ng/mL doxycycline and
RNA was isolated over time. Show is gene expression of the target gene
measured by RT-PCR.

We tested the impact of IFI27 expression on Monomac1 apoptosis
outcome (constitutive and etoposide-induced) (Figure 4.8). IFI27 and MCS cell
lines were treated with doxycycline (1000 ng/mL, 8 hours), inducing expression in
the IFI27 line (data not shown), followed by etoposide apoptosis challenge (18
hour, 0, 1, and 5 μg/mL) (Figure 4.8A-B). Data show similar constitutive and
etoposide-challenged apoptosis response in the presence (IFI27-Doxy) or
absence (MCS-Doxy) of IFI27 expression (Figure 4.8A-B) and in un-induced
conditions (IFI27-None) (Figure 4.8B). We also monitored apoptosis in the IFI27
cell line (relative to untransduced Monomac1) over a 14 hour gene induction
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Figure 4.8: IFI27 transgene expression and apoptosis outcome in
Monomac1 cells.
(A) Shown are apoptosis plots (active caspase-3 versus 7-AAD) of the MCScontrol (top row) and IFI27 (bottom row) cell lines treated with 1000 ng/mL
doxycycline for 8 hours, washed, and challenged overnight (18 hr) with 0, 1, or 5
μg/mL etoposide. (B) Quantification of induction-challenge experiment in (A) with
doxy-induced MCS (green), doxy-induced IFI27 (purple), un-induced-MCS (blue),
and un-induced IFI27 (red). (C) Time-course of untransduced and IFI27 cell line.
Gene-expression was induced in all conditions (1000 ng/mL doxycycline) and
cells were untreated or etoposide-challenge (6 μg/mL) at 9 hours.
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(1000 ng/mL doxycycline) with etoposide apoptotic challenge (6 μg/mL)
beginning at 9 hours and, again, did not detect augmentation of apoptosis in the
presence of IFI27 gene expression (Figure 4.8C).

Based on the described function of IFI27, we sought to determine if IFI27
expression had any upstream effect on mitochondrial membrane potential (195).
IFI27 and MCS cell lines were treated with doxycycline (250 ng/mL, 4 hours).
Cells were challenged with etoposide (600 ng/mL) and mitochondrial membrane
potential (MitoProbe DilC1) and apoptosis (Annexin V) were monitored for 24
hours (Figure 4.9). Disruption of membrane potential, measured as the percent of
MitoTracker-negative cells of the transduced population (mCherry+, GFP+), was
observed in both MCS and IFI27 cell lines at 24 hours at 41.7% and 41.1%
(etoposide challenged) and 9.7%, 9.3% (no challenge), respectively. No
differences were detected at any time point (n=3 internal replicates). These data
show expression of the IFI27 transgene did not have a detectable impact on
mitochondrial membrane potential or augment apoptosis outcome in the
Monomac1 cell line.

Multiple IFI6 expression-apoptosis experiments were conducted in parallel
(CdCl2/etoposide induction, caspase-3/MitoProbe detection) and yielded a similar
lack of relationship between gene expression and function outcome (data not
shown).
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Figure 4.9: IFI27 transgene expression and mitochondrial membrane
potential measurement.
(A) MCS-control (top row) and IFI27 (bottom row) cell lines treated with 250
ng/mL doxycycline for 4 hours, washed, etoposide-challenged (600 ng/mL), and
assayed for apoptosis at 0, 1, 2, 4, and 24 hours post etoposide.
MitoTrackerDilC1 (x-axis) shows cells with (Mito+) and without (Mito-)
mitochondrial membrane potential. Annexin-V is shown on the y-axis. (B) The
amount of Mito- cells as a percentage of the dual-fluorescent population is shown
in MCS (circle) and IFI27 (square) cell lines after etoposide treatment over 24
hours (n=3 internal replicates).
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4.4 Discussion, limitations, and future directions
Expression of pro-apoptotic ISG12 genes (IFI27), which was observed in
viremic patients in relation to elevated apoptosis (Chapter 2), did directly affect
apoptosis regulation in the monocyte Monomac1 cell line in vitro. Thus, our data
do not support the hypothesis that IFI27 over-expression would augment
apoptosis outcome in vitro. The finding that single gene over-expression was not
sufficient to impact apoptosis reinforces the interpretation that multiple genes (i.e.
ISG12, Bcl2) induced with immune and viral pressure may account for regulation
of apoptosis outcome in vivo (Chapter 2).

While our data do not support reports of functional links between
expression IFI6 and IFI27 and mitochondrial membrane potential and apoptosis
outcome (191-193, 228), experimental limitations and considerations may qualify
our interpretation. First, while we demonstrated the induction of IFI27 RNA
expression, we did not have suitable tools to confirm IFI27 protein expression.
Second, our over-expression system does not preclude that gene knockdown in
primary cells would not yield an apoptosis phenotype, as was demonstrated for
Rb1 in primary HIV (-) monocytes (105). Third, the Monomac1 system, while
chosen for control and reproducibility, introduces its own limitations in
interpretation as a cancer cell line as oncogenic and pro-survival mutations and
gene expression in a cell line may maintain viability to a point that cannot be
overcome by over-expression of IFI27.
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This suggests follow-up work in primary monocytes and macrophages,
while presenting challenges in gene delivery/expression and/or gene knockdown,
may still be required to support or refute a positive impact of the genes described
here. The association of monocyte ISG expression and apoptosis with HIV-1
clinical metrics (established in chapter 2) would allow future studies to test the
impact of IFI27 gene knockdown ex vivo. With optimized reagents and sufficient
material, the impact of multiple candidate genes, highlighted in chapter 2, could
be tested simultaneously.

In summary, we established Monomac1 cells lines for the doxycyclineinducible expression of the apoptosis regulatory ISG12 genes, IFI6 and IFI27.
Despite robust gene expression, we did not detect an impact on mitochondrial
membrane potential or apoptosis outcome in this system. Our data suggest gene
knockdown in primary monocytes may be a superior approach to address the
mechanistic roles of IFI6 and IFI27 in the regulation of monocyte apoptosis.

4.5 Materials

4.5.1 Generation of inducible expression Monomac1 cell lines
IFI6 and IFI27 gene fragments were engineered with 5’ BamHI and 3’
Nhe1 restriction sites by PCR amplification from commercially obtained
templates (Open Biosystems, clone ID 4654295 and 6495362 for IFI6 and IFI27)
(Figure 4.1). The expression vectors pLU-EF1aL-rtTA3-iCherry (“helper plasmid”)
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and pLU-TREmin-MCS-pGFP (“transducing plasmid”) were obtained from the
Wistar Protein Expression Core. Gene fragments were ligated into the
transducing plasmid and packaged in a VSV-delivery system for transduction
(Wistar Protein Expression Core). We validated hPGK promoter activity
(transducing plasmid) in the Monomac1 cell line (data not shown). The
transduced cell lines (GFP, mCherry, MCS, IFI6, and IFI27) were sorted using
the University of Pennsylvania Flow Cytometry Core (Figure 4.4A-B).
Transduction for sort was scaled up to 4 million cells per single transduction and
20 million cells per co-transduction. Gene expression was quantified by RT-PCR
as done in Section 2.5.5. The primers used to detect Rb1, Mx1, IFI6, and IFI27
(Figure 4.6) are detailed in Table 2.4.

4.5.2 Apoptosis induction in transduced Monomac1 cell lines
Gene expression induction (doxycycline) and apoptosis challenge (CdCl2,
etoposide) were optimized over multiple experiments. Experiments shown
(Figure 4.8, 4.9) were conducted at 250-1000 ng/mL doxycycline and 0.6 to 6
ug/mL etoposide. Caspase-3 and Annexin-V apoptosis detection antibodies (BD
Biosciences) and MitoProbe DilC1 (ThermoFischer) were used per the
manufacturers’ instructions. Samples were prepared for flow cytometry as in
Section 2.5.6. Up to 100,000 events were analyzed on a 14-color LSR II (BD
Biosciences). Flow cytometry data analysis was performed with FlowJo software
(TreeStar).
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Chapter 5: Conclusions and future directions
5.1 Summary of main findings
5.2 Context
5.2.1 “High viremia” monocytes apoptosis: ISG expression and innate
activation, common denominators
5.2.2 Reversal of monocyte/macrophage activation during advanced
infection: Filling in the picture
5.3 Future Directions
5.3.1 Elucidating immune and viral pressures driving monocyte apoptosis
5.3.2 Macrophages: Targeting tissue activation and apoptosis
5.4 The role of HIV-1 disease state and viral/immunological pressures on
monocyte apoptosis and monocyte/macrophage activation
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5.1 Summary of main findings
In this dissertation, we focused on changes in apoptosis and activation in
circulating monocytes during HIV-1 infection between low and high viremic
patients and from pre-ART to ART suppressed conditions. The role of monocytes
and macrophages in pathogenesis has been a focal point of the HIV research
field for decades. However, investigations of the impact of HIV/SIV infection and
virus-cell interactions on monocyte apoptotic outcome generated seemingly
conflicting findings between in vitro studies, NHP models, and ex vivo patient
cohort studies. Additionally, the description of HIV-1-associated microbial
translocation has highlighted the presence and clinical significance of innate
immune activation during HIV-1 infection. ART-mediated reversal of
monocyte/macrophage activation during advanced infection has been
understudied. To address the degree of monocyte apoptosis during high viremia,
reversal of monocyte/macrophage activation during ART, and underlying
mechanisms, we performed the following sets of experiments:
1. We investigated ex vivo monocyte apoptosis from low and high viral
load HIV (+) patients and performed hypothesis-generating RNA
sequencing.
2. We validated a shift in ex vivo monocyte apoptosis observed in high
viral load conditions and investigated target gene expression in a
broader HIV (+) cohort.
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3. We examined the ART-mediated reversal of monocyte/macrophage
activation during advanced HIV-1 infection in the presence and
absence of CCR5 antagonism (Maraviroc).
4. We tested the impact of the ISG12 genes IFI6 and IFI27 as a possible
underlying mechanism regulating monocyte apoptosis in the context of
HIV-1 infection.

We show, for the first time, that monocyte apoptosis is elevated in HIV (+)
patients with viral loads above 40,000 HIV-1 copies/mL. The impetus to
investigate apoptosis at high HIV-1 viral loads arose from the seemingly
incongruous reports of anti-apoptotic impacts of HIV-1 infection on monocytes in
vivo/ex vivo (103-105) and increased monocyte turnover and pro-apoptotic
outcomes in SIV-NHP and in vitro HIV-1 studies (70, 71, 96). Furthermore,
decreased monocyte viability may represent a source of monocyte dysfunction
during advanced infection (97). Consequently, we initiated a pilot study to
investigate CD4 T-cell and monocyte apoptosis and examine gene expression by
RNA sequencing in HIV (+) patients with elevated viremia, and collected
preliminary data suggesting apoptosis resistance observed during low, steadystate viral load may shift to heightened apoptosis sensitivity at high viral loads.
RNA sequencing analysis highlighted multiple gene families and genes, such as
IFI6 and IFI27, for follow-up analysis that may regulate monocyte apoptosis
during HIV-1 infection.
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It remained to be determined if a shift in monocyte apoptosis could be
confirmed in a HIV (+) cohort spanning a broad spectrum of viral load and CD4
count, and if detected, how a potential distribution of monocyte apoptosis
sensitivity would be related to better-described monocyte/macrophage
phenotypes during HIV-1 infection, including ISG expression (Section 1.4) and
cell-associated and soluble markers of activation (Section 1.5). In a crosssectional cohort of HIV (+) individuals (n=35), we confirmed elevated constitutive
and induced monocyte apoptosis in patients above 40,000 HIV-1 copies/mL and
modeled the distribution of apoptosis outcome using observed changes in viral
load and p53, ISG, and Bcl2 family gene expression (Chapter 2). Future studies
in acute infection, elite controllers, and longitudinal ART cohorts (Chapter 3) may
help determine the contributions of viremia, monocyte ISG expression, and
innate immune activation in driving monocyte apoptosis outcome during HIV-1
disease.

Next, we demonstrated differential reversal of cell-associated and soluble
monocyte and macrophage activation biomarkers during ART in advanced HIV-1
infection (Chapter 3). We monitored biomarkers of T-cell activation,
monocyte/macrophage activation (cell-associated and soluble), monocyte ISG
expression, and correlates of monocyte apoptosis outcome in an advanced HIV1 infection cohort (n=65) characterized by baseline CD4 count below 100
cells/mm3 and viral suppression after 24 weeks ART. We also determined the
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impact of CCR5 antagonism (ART versus ART + Maraviroc) on markers of T-cell
and monocyte/macrophage activation and CCR5 expression in PBMC.

We did not detect an impact of Maraviroc on markers of T-cell activation or
monocyte/macrophage activation, excluding a minor effect on CD4 T-cell
activation, above ART alone. We did observe a higher percentage of CCR5
expressing CD4 T-cells, CD8 T-cells, and monocytes in PBMC of the Maraviroc
group during ART. As we did not examine tissue activation, as done elsewhere
(217), we do not exclude a long-term impact of CCR5 antagonism on tissue
damage, repair, and reconstitution, as should be a focus of future studies.

We show decreasing monocyte ISG expression is closely associated with
decreased CD8 T-cell activation and greater relative reductions in cell-associated
biomarkers of monocyte activation (CD14++CD16+ monocytes, CD163) compared
to plasma soluble markers of monocyte/macrophage activation (sCD14,
sCD163). The lack of greater change in both sCD14 and sCD163 after ART in
advanced infection supports that microbial translocation and associated
activation may be of greater concern in advanced infection independent of viral
suppression. Our data highlight the benefits of viral suppression in advanced
infection despite sub 200-CD4 reconstitution at 24 weeks and may provide
monocyte immune reconstitution benchmarks, such as monocyte CD163
expression, that can be monitored to inform CD4 recovery (Chapter 3).
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Lastly, we show over-expression of IFI6 or IFI27, candidate ISGs
regulating apoptosis outcome and expressed in monocytes of patients with viral
loads above 40,000 HIV-1 copies/mL, is insufficient to augment apoptosis
outcome in a monocyte cell line in vitro (Chapter 4). This suggests single-gene
over-expression fails to recapitulate the multi-family gene expression changes
(Bcl2, p53, ISG) that may be required to affect apoptosis deregulation in vivo or
simply cannot overcome the intrinsic transforming/survival pressures of the
Monomac1 cell line used. An alternative hypothesis is the in the in vitro system
used does not deliver a secondary stress or inflammatory signal required to
observe an effect on apoptotic outcome. This is supported by the observation
that monocyte-derived macrophages matured in the presence of HIV-1, GMCSF, and IL-6 are sensitized to LPS/IFN-γ induced apoptosis (96).

Findings presented in chapter 2 suggest the presence of at least two
distinct phases of monocyte/macrophage apoptosis and activation during
untreated infection (Figure 5.1): (1) below 40,000 HIV-1 copies/mL, characterized
by increases in plasma sCD163 and the CD14++16+ monocyte subset, Rb1
expression, and maintained viability (as described in (103-105)), and (2) above
40,000 HIV-1 copies/mL, described here, characterized by increasing plasma
sCD14 with viral load, high ISG expression, and elevated apoptosis.
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Figure 5.1: Model of monocyte apoptosis and activation during chronic,
untreated HIV-1 infection.
Shown are clinical and monocyte apoptosis, ISG, and activation profiles with low
(left) and high viremia (right) during chronic, untreated HIV-1 infection.

Our ART study indicates that monocyte/macrophage biomarkers of
activation, often interpreted jointly, exhibit a differential reversal and may reflect
distinct mechanisms of activation. These findings support a working model with a
spectrum of reversal of monocyte/macrophage activation biomarkers (Figure 5.2,
Chapter 3). At one end, we interpret categorical resolution of monocyte CD169
expression by 12 weeks closely mirrors suppression of plasma viremia, followed
by decreases in the remaining monocyte cell-associated markers and T-cell
activation markers. On the other end of the spectrum, sCD14 and sCD163 may
represent more clinically significant biomarkers of residual immune cross-talk and
microbial translocation associated ligands (such as LPS) that may or may not be
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Figure 5.2: Spectrum model of monocyte/macrophage activation
biomarkers during ART in advanced HIV-1 infection.
Shown is a simplified model of reversal of monocyte/macrophage activation
markers during ART and potential viral and immunological drivers.

efficiently reversed with ART in advanced infection. Finally, although these
findings represent independent cross-sectional and longitudinal studies, we can
supplement our initial model to generate a simplified representation of the
plasticity of monocyte apoptosis and activation with HIV-1 infection state (Figure
5.3).

Taken together, our work demonstrates monocyte/macrophage apoptosis
outcomes and activation markers are a complex reflection of infection state and
the associated collection of underlying host and pathogen pressures.
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Figure 5.3: Model of monocyte/macrophage apoptosis and activation
relative to HIV-1 infection state.
Shown is an extension of Figure 5.1 to include impact of ART-mediated viral
suppression (right) in addition to low viremia (left) and high viremia (center)
during untreated, chronic HIV-1 infection.

5.2 Context

5.2.1 “High viremia” monocytes apoptosis: ISG expression and innate
activation, common denominators
Our description of elevated apoptosis in monocytes from HIV (+) patients
with viral loads above 40,000 HIV-1 copies/mL highlights underlying themes in
previous monocyte apoptosis studies in NHP-SIV, HIV, and in vitro systems (70,
71, 96, 99). Elevated “off-ART” constitutive apoptosis (compared to HIV (-)
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individuals) was observed in a small but broad viral load cohort (n=10, mean viral
load = 94,000 HIV-1 copies/mL, range = 6,000-300,000 HIV-1 copies/mL) (99).
Elevated STAT1 protein expression in the “off-ART” group and the association of
STAT1 expression with apoptosis outcome in this group align with our findings of
elevated ISG expression and monocyte apoptosis in high viral load patients
within our HIV (+) cohort.

A pro-apoptotic impact of HIV-1 in vitro has been demonstrated when
monocytes are differentiated in the presence of HIV-1 (Bal), GM-CSF, and IL-6,
sensitizing them to activation-induced (IFN-γ/LPS) apoptosis (compared to GMCSF, IL-6 conditions alone) (96). Although we did not measure plasma IL-6 and
LPS in our study, plasma sCD14 was associated with viral load (Figure 2.11C),
and elevated plasma IL-6 in both viremic and ART-suppressed patients
(compared to HIV (-) individuals) has been described elsewhere (35). We
interpret this in vitro system may mimic inflammatory and activation pressures
present during high HIV-1 viremia in vivo.

Our data join an increasing body of evidence suggesting that high HIV/SIV
viral load and low CD4 count may be associated with changes in monocyte
functional responses, including greater monocyte turnover (associated with
plasma sCD163) (70, 71), tissue migration (70, 71, 94), and macrophage
apoptosis in tissue (70). This study complements studies in SIV-infected
macaques (using in vivo BrdU labeling) in which disease progression (i.e. high
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viral load) was associated with increased monocyte turnover, associated with
higher tissue apoptosis (70). Overall, our data suggest as viral load rises, added
TLR-mediated activation and/or ISG induction may override existing antiapoptotic mechanisms, resulting in higher monocyte turnover.

5.2.2 Reversal of monocyte/macrophage activation during advanced
infection: Filling in the picture
First described almost a decade ago (86), microbial translocation and
associated immune activation during HIV-1 infection have been established as a
strong predictor of mortality (91, 92) and are associated with CNS pathogenesis
(77) and immune dysfunction (211). Incomplete resolution of
monocyte/macrophage activation after ART described here (advanced infection)
and elsewhere (Table 3.1) supports persistence of innate activation despite viral
suppression.

Here we show reversal of activated monocyte subsets and markers of ISG
expression despite nadir CD4 counts below 100 cells/mm3, highlighting early
immunological benefits of ART in advanced infection. Nonetheless, the
persistence of sCD14 during ART as an indicator of lasting microbial
translocation supports the investigation of interventions targeting innate
activation. Recently, two clinical trials targeting vascular inflammation in HIV (+)
cohorts demonstrated clinical benefit regarding reversal of innate immune
activation. First, the integrase inhibitor, Elvitegravir reduced sCD14 beyond
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standard ART alone (238). Second, addition of Rosuvastatin to a standard ART
regimen reduced sCD14, the non-classical (CD14+CD16++) monocyte subset,
plasma CXCL10, and CD4 and CD8 T-cell activation over placebo (239, 240).
Our data demonstrating elevated innate immune activation with increasing viral
load (Chapter 2) and the persistence of innate activation despite suppressive
ART in advanced infection (Chapter 3), reinforce the significance of the
development of these next generation ART strategies.

5.3 Future Directions

5.3.1 Elucidating immune and viral pressures driving monocyte apoptosis
The HIV (+) cohort in this thesis with elevated monocyte apoptosis at high
viral loads (Chapter 2) represents HIV-1 disease with high viremia, evidence of
innate immune activation and microbial translocation (Figure 2.11, 2.12), and ISG
expression (Table 2.4, Figure 2.13) (absent symptomatic opportunistic infection).
The impact of ART initiated from high viral load on monocyte apoptosis remains
to be described directly. Our data (Chapter 3) suggest ART-mediated viral
suppression and ISG reversal proceed reversal of TLR-mediated activation,
allowing one to investigate the impact of residual TLR-mediated activation on
monocyte apoptosis in the absence of viremia and ISG expression. Interestingly,
cross-sectional data from our lab show induced monocyte apoptosis is higher in
ART-patients than a low level viremic cohort (median viral load = 13,468 HIV-1
copies/mL) (and evidence loss off anti-apoptotic Rb1 activity with ART) (105).
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Conversely, characterization of monocyte apoptosis in patients during acute
infection would evaluate the impact of peak viremia and ISG expression absent
established microbial translocation (86).

5.3.2 Macrophages: Targeting tissue activation and apoptosis
Recently, attention has focuses on HIV-1 tissue reservoirs as a significant
challenge to the cure initiative, within which macrophages play a major role (49,
241, 242). The degree to which monocyte apoptosis (Chapter 2) and activation
phenotypes (Chapter 2, Chapter 3) extend to tissue macrophages have
significant implications regarding pathogenesis and viral reservoirs.

While macrophage apoptosis has been described in CNS and lymph
nodes during SIV NHP infection (70, 95), direct measurements during HIV-1
infection have been limited. Future studies should take advantages of lymph
node and rectal biopsy techniques to determine the degree of macrophage
apoptosis in tissue during viremic and ART-suppressed HIV-1 infection. Such
studies would inform potential contributions of macrophage apoptosis/dysfunction
to gut epithelial barrier damage (88, 93, 94) and the development of opportunistic
infection.

On a related note, tissue characterization of macrophage activation may
similarly inform on gut epithelial barrier damage and microbial translocation (88,
93, 94). Additionally, these studies could determine if retention of tissue
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macrophage activation is associated with, and may contribute to, the size and
persistence of the HIV-1 tissue reservoir in both CD4 T-cells and macrophages.
This will inform the relationship between innate activation in tissue and viral
persistence and may highlight mechanisms important in targeting the HIV-1
tissue reservoir.

5.4 The role of HIV-1 disease state and viral/immunological pressures on
monocyte apoptosis and monocyte/macrophage activation
The work presented in this dissertation demonstrates the plasticity of
monocyte/macrophage apoptosis and activation markers and their association
with the stage of HIV-1 infection and infection-associated pressures (viremia, ISG
expression, and microbial translocation). Previous studies and work presented
here suggest the apoptotic fate of monocytes may represent a barometer of
immune stress manifest during infection in vivo. Additionally, the spectrum of
reversal of different biomarkers of monocyte/macrophage activation with ART
may be useful in informing both immune reconstitution and the persistence of
microbial translocation and associated activation.

Understanding the immunological and viral pressures driving functional
changes in monocytes and macrophages will be vital in the targeting and
reversing HIV-1 associated innate immune activation.
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